<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4988628</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0160517</article-id><article-id pub-id-type="publisher-id">PONE-D-16-16320</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Chromosome biology</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biotechnology</subject><subj-group><subject>Genetic Engineering</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biotechnology</subject><subj-group><subject>Bioengineering</subject><subj-group><subject>Tissue Engineering</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Bioengineering</subject><subj-group><subject>Tissue Engineering</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Protein Domains</subject><subj-group><subject>Homeobox</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject><subj-group><subject>Gene Regulation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>Small nucleolar RNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>Small nucleolar RNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Organism Development</subject><subj-group><subject>Aging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Aging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Aging</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Decoding the Regulatory Landscape of Ageing in Musculoskeletal Engineered Tissues Using Genome-Wide DNA Methylation and RNASeq</article-title><alt-title alt-title-type="running-head">Ageing Engineered Tissues</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Peffers</surname><given-names>Mandy Jayne</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Goljanek-Whysall</surname><given-names>Katarzyna</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Yongxiang</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rushton</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Loughlin</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Proctor</surname><given-names>Carole</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Clegg</surname><given-names>Peter David</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Institute of Ageing and Chronic Disease, University of Liverpool, Leahurst, Chester High Road, Neston, Wirral, UK, CH64 7TE</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Thurston Arthritis Research Centre, School Of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 27599</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Centre for Genomic Research, Institute of Integrative Biology, Biosciences Building, Crown Street, University of Liverpool, Liverpool, UK, L69 7ZB</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, NE2 4HH</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Newcastle University Institute for Ageing, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK, NE4 5PL</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Gronthos</surname><given-names>Stan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>The University of Adelaide, AUSTRALIA</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>
<list list-type="simple"><list-item><p><bold>Conceptualization:</bold> MJP PDC JL</p></list-item><list-item><p><bold>Data curation:</bold> YF MJP</p></list-item><list-item><p><bold>Formal analysis:</bold> MJP KGW JL MR YF CP</p></list-item><list-item><p><bold>Funding acquisition:</bold> MJP PDC JL CP</p></list-item><list-item><p><bold>Investigation:</bold> MJP JC KGW</p></list-item><list-item><p><bold>Methodology:</bold> MJP MR YF KGW</p></list-item><list-item><p><bold>Project administration:</bold> MJP JC</p></list-item><list-item><p><bold>Resources:</bold> MJP PDC JL CP</p></list-item><list-item><p><bold>Supervision:</bold> MJP PDC</p></list-item><list-item><p><bold>Validation:</bold> MJP KGW</p></list-item><list-item><p><bold>Writing - original draft:</bold> MJP</p></list-item><list-item><p><bold>Writing - review &#x00026; editing:</bold> MJP.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>peffs@liv.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>8</issue><elocation-id>e0160517</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Peffers et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Peffers et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0160517.pdf"/><abstract><p>Mesenchymal stem cells (MSC) are capable of multipotent differentiation into connective tissues and as such are an attractive source for autologous cell-based regenerative medicine and tissue engineering. Epigenetic mechanisms, like DNA methylation, contribute to the changes in gene expression in ageing. However there was a lack of sufficient knowledge of the role that differential methylation plays during chondrogenic, osteogenic and tenogenic differentiation from ageing MSCs. This study undertook genome level determination of the effects of DNA methylation on expression in engineered tissues from chronologically aged MSCs. We compiled unique DNA methylation signatures from chondrogenic, osteogenic, and tenogenic engineered tissues derived from young; n = 4 (21.8 years &#x000b1; 2.4 SD) and old; n = 4 (65.5 years&#x000b1;8.3SD) human MSCs donors using the Illumina HumanMethylation 450 Beadchip arrays and compared these to gene expression by RNA sequencing. Unique and common signatures of global DNA methylation were identified. There were 201, 67 and 32 chondrogenic, osteogenic and tenogenic age-related DE protein-coding genes respectively. Findings inferred the nature of the transcript networks was predominantly for &#x02018;cell death and survival&#x02019;, &#x02018;cell morphology&#x02019;, and &#x02018;cell growth and proliferation&#x02019;. Further studies are required to validate if this gene expression effect translates to cell events. Alternative splicing (AS) was dysregulated in ageing with 119, 21 and 9 differential splicing events identified in chondrogenic, osteogenic and tenogenic respectively, and enrichment in genes associated principally with metabolic processes. Gene ontology analysis of differentially methylated loci indicated age-related enrichment for all engineered tissue types in &#x02018;skeletal system morphogenesis&#x02019;, &#x02018;regulation of cell proliferation&#x02019; and &#x02018;regulation of transcription&#x02019; suggesting that dynamic epigenetic modifications may occur in genes associated with shared and distinct pathways dependent upon engineered tissue type. An altered phenotype in engineered tissues was observed with ageing at numerous levels. These changes represent novel insights into the ageing process, with implications for stem cell therapies in older patients. In addition we have identified a number of tissue-dependant pathways, which warrant further studies.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Wellcome Trust (GB)</institution></funding-source><award-id>WT088557MA)</award-id><principal-award-recipient><name><surname>Peffers</surname><given-names>Mandy Jayne</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Medical Research Council (MRC) and Arthritis Research UK as part of the MRC &#x02013; Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA).</institution></funding-source><principal-award-recipient><name><surname>Peffers</surname><given-names>Mandy Jayne</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the Wellcome Trust <ext-link ext-link-type="uri" xlink:href="http://www.welccometrust.ac.uk">www.welccometrust.ac.uk</ext-link> (WT088557MA) to MJP, Medical Research Council (MRC) and Arthritis Research UK as part of the MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA) <ext-link ext-link-type="uri" xlink:href="http://www.cimauk.org">www.cimauk.org</ext-link> to MJP, JC, KW, CP, JL, MR, PDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="10"/><page-count count="33"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Sequence data have been submitted to National Centre for Biotechnology Information Gene Expression Omnibus (NCBI GEO) under Array Express accession number E-MTAB-3427.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Sequence data have been submitted to National Centre for Biotechnology Information Gene Expression Omnibus (NCBI GEO) under Array Express accession number E-MTAB-3427.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The limited ability of articular cartilage, bone and tendon to regenerate has prompted the development of cell-based tissue engineering techniques. One cell therapy option is mesenchymal stem cells (MSC); a heterogeneous population of multi-potent cells with the ability to differentiation into tissues including cartilage, bone and tendon, thus accommodating tissue repair and homeostasis. The principles of tissue engineering involve a multifarious interaction of factors, and knowledge of the extent MSC phenotype and differentiation capacity alter with ageing is limited. Subsequently, any loss in functionality with age would have profound consequences for the maintenance of tissue viability and the quality of tissues. MSCs have been utilised in clinical trials of cell therapies for cartilage repair and osteoarthritis (reviewed [<xref rid="pone.0160517.ref001" ref-type="bibr">1</xref>]), bone fracture treatment [<xref rid="pone.0160517.ref002" ref-type="bibr">2</xref>] and in a limited number of tendon therapies [<xref rid="pone.0160517.ref003" ref-type="bibr">3</xref>]. However, the therapeutic efficiency of MSCs for clinical applications remains limited, possibly due to the attenuation of their regenerative potential in aged patients with chronic diseases.</p><p>Advancing age is a prominent risk factor that is closely linked with the onset and progression of diseases such as osteoarthritis, osteoporosis and tendinopathy. Understanding the influence that ageing has on chondrogenic, osteogenic and tenogenic progenitor cells such as MSCs is important in determining how these processes affect their capacity to differentiate into functional chondrocytes, osteoblasts and tenocytes for use in therapeutic applications. A model using MSCs derived from young and old donors to musculoskeletal engineered tissues could aid in our understanding of musculoskeletal ageing.</p><p>To understand the underlying mechanisms that are responsible for age-related changes in musculoskeletal engineered tissues, a number of studies have been undertaken on ageing MSCs (reviewed [<xref rid="pone.0160517.ref004" ref-type="bibr">4</xref>]), as well as the differentiation potential of tissue engineered cartilage [<xref rid="pone.0160517.ref005" ref-type="bibr">5</xref>] and bone [<xref rid="pone.0160517.ref006" ref-type="bibr">6</xref>], though no studies have addressed these questions in tendon.</p><p>There are a few studies investigating the effect of chronological age of donor MSC on engineered tissues, some with conflicting findings. One study found a reduction in glycosaminoglycans in chondrogenesis with age [<xref rid="pone.0160517.ref007" ref-type="bibr">7</xref>] whereas another experiment using a wider donor age-range found no change [<xref rid="pone.0160517.ref008" ref-type="bibr">8</xref>]. Contrasting results of the chondrogenic differentiation potential of adult MSCs has been described with one study reporting age independence [<xref rid="pone.0160517.ref009" ref-type="bibr">9</xref>], whilst another demonstrated a negative correlation with advancing age in male but not female donors [<xref rid="pone.0160517.ref010" ref-type="bibr">10</xref>]. A study demonstrated that foetal and adult MSCs are differentially regulated by transforming growth factor-&#x003b2; stimuli to activate the onset of chondrogenesis, suggesting that discrete age-related mechanisms direct chondrogenic regulation following development and postnatal maturation [<xref rid="pone.0160517.ref011" ref-type="bibr">11</xref>].</p><p>Age-related changes in osteogenesis have been more widely studied. Osteogenic progenitors in MSCs derived from rat bone marrow demonstrated an age-related decline. In addition MSCs from young rats had a significantly greater bone formation capability <italic>in vivo</italic> compared with aged rats [<xref rid="pone.0160517.ref012" ref-type="bibr">12</xref>]. The osteogenic potential of MSCs is independent of advancing age in adult human donors [<xref rid="pone.0160517.ref013" ref-type="bibr">13</xref>]. However, a decline in the osteogenic precursor population, due to accelerated senescence and lower rate of population doublings in MSCs isolated from older donors suggests a reduction in osteoblast formation. This may contribute to the age-related reduction in bone formation in the elderly [<xref rid="pone.0160517.ref014" ref-type="bibr">14</xref>]. In age-related studies of osteogenic differentiation one group identified an increase in alkaline phosphatase with age [<xref rid="pone.0160517.ref015" ref-type="bibr">15</xref>] whilst another demonstrated a decrease [<xref rid="pone.0160517.ref016" ref-type="bibr">16</xref>]. It is thought these discrepancies could be due to the heterogeneous population which is propagated within and amongst donor populations.</p><p>Few studies have investigated the effects of ageing MSCs on tendon tissue engineering. However, one study on human tendon stem cells from aged tendons described reduced proliferation capacity and premature entry into senescence [<xref rid="pone.0160517.ref017" ref-type="bibr">17</xref>]. A recent study in rat tendon-derived stem cells from older donors demonstrated earlier entry into senescence which was postulated to be due to a reduction in the levels of miRNA-135a, a ROCK-1 targeting microRNA (miR) that blocks entry into senescence pathways. This may be due to a reduction in miR-135a, which binds to ROCK-1 and inhibits entry into senescence in young tendon. Thus a decrease in miR-135a in older tendon may be the cause of reduced stem cell proliferation, self-renewal and tenogenic differentiation [<xref rid="pone.0160517.ref018" ref-type="bibr">18</xref>].</p><p>The advent of global DNA methylation arrays and RNASeq studies have made it possible to explore gene methylation and/or expression during cell development [<xref rid="pone.0160517.ref019" ref-type="bibr">19</xref>], tissue differentiation [<xref rid="pone.0160517.ref020" ref-type="bibr">20</xref>], disease [<xref rid="pone.0160517.ref021" ref-type="bibr">21</xref>] and ageing [<xref rid="pone.0160517.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>]. In addition, the global relationship between gene methylation and expression can now be investigated in ageing [<xref rid="pone.0160517.ref024" ref-type="bibr">24</xref>]. Whilst global methylation and RNASeq are powerful tools to study methylation variation and transcription changes, no joint analysis with these two types of data have been reported in tissue engineering. Tissue engineering aims to develop biomimetic tissues that recapitulate biological, structural and functional characteristics of native tissue. Thus age-related changes have potential implications for the tissue engineering strategies used for enhancing musculoskeletal repair. In this study we evaluated and compared the methylome and transcriptome of chondrogenic, osteogenic and tenogenic engineered tissues derived from young and old human bone marrow derived MSCs in order to determine similar and distinct changes with ageing. In doing so we have identified areas for future research to improve functionality of ageing MSC derived engineered tissues.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><p>All chemicals are supplied by Sigma unless stated otherwise.</p><sec id="sec003"><title>Cell Culture and Differentiation</title><p>Human MSCs from young; n = 4 (21.8years&#x000b1;2.4SD) and old; n = 4 (65.5years&#x000b1;8.3SD) donors (Stem Cell Technologies, Grenoble, France and Promocell, Heidelberg, Germany), grown to passage 4 and each donor each differentiated into chondrogenic [<xref rid="pone.0160517.ref025" ref-type="bibr">25</xref>], osteogenic [<xref rid="pone.0160517.ref026" ref-type="bibr">26</xref>] and tenogenic [<xref rid="pone.0160517.ref027" ref-type="bibr">27</xref>] tissues as previously described and used in all subsequent experiments [<xref rid="pone.0160517.ref028" ref-type="bibr">28</xref>]. All tissue culture was undertaken in 5% oxygen and tissues harvested at 21 days (osteogenic) and 28 days (chondrogenic and tenogenic). All cells were purchased and thus ethical approval was not required.</p></sec><sec id="sec004"><title>Validation of differentiation</title><p>Differentiation of chondrogenic and osteogenic engineered tissues was assessed by comparing to MSCs treated identically except with maintenance media (complete Dulbecco&#x02019;s Modified Eagles Media (Gibco)) using histology, and quantitative real-time PCR (qRT-PCR). Calcium depositions were determined in osteogenic tissues using Alizarin red staining as previously described [<xref rid="pone.0160517.ref029" ref-type="bibr">29</xref>]. Chondrogenic pellets were paraffin embedded and 4 &#x003bc;m sections taken and further stained with Alcian Blue/Nuclear Fast Red. Tendon engineered tissues were fixed in 4% paraformaldehyde, longitudinally embedded in paraffin and 4&#x003bc;m sectioned on polylysine slides. Staining was undertaken with Masson&#x02019;s Trichrome [<xref rid="pone.0160517.ref030" ref-type="bibr">30</xref>].</p><p>Transmission electron microscopy (TEM) of tendon tissues were performed by fixation in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer followed for 8 hours, followed by buffer washing procedure and second fixation and contrast stain with 0.1% osmium tetroxide for 90 minutes. Samples were stained with 8% uranyl acetate in 0.69% maleic acid for 90 minutes, dehydrated in ascending ethanol concentrations and embedded in epoxy resin. 60&#x02013;90 nm sections were cut with a Reichert- Jung Ultracut on an ultramicrotome using a diamond knife, mounted on 200 mesh copper grids and stained with &#x02018;Reynold&#x02019;s Lead citrate&#x02019; stain for 4 minutes. Images were viewed in Philips EM208S Transmission Electron Microscope at 80k.</p><p>RNA was extracted from all assays and converted to cDNA to analyse lineage-specific gene expression markers using qRT-PCR relative to GAPDH [<xref rid="pone.0160517.ref022" ref-type="bibr">22</xref>]. All primer sequences are in <xref ref-type="supplementary-material" rid="pone.0160517.s001">S1 file</xref>.</p></sec><sec id="sec005"><title>RNA isolation, library preparation for RNASeq and small RNASeq and sequencing</title><p>Total RNA was isolated using TRIzol (Invitrogen<sup>&#x02122;</sup> Life Technologies, Carlsbad, USA) [<xref rid="pone.0160517.ref031" ref-type="bibr">31</xref>] and purified using RNeasy spin columns with on-column DNase treatment (Qiagen, Crawley, UK). Sequencing used the Illumina HiSeq 2000 (Illumina, San Diego, USA) at 2 &#x000d7; 100-base pair (bp) paired-end sequencing with v3 chemistry for RNASeq. Multiplexed size selected small RNA library pools were sequenced on one lane of the Illumina HiSeq 2500 (Illumina, San Diego, USA) at 1x50 bp sequencing. Details are in <xref ref-type="supplementary-material" rid="pone.0160517.s002">S2 file</xref> and [<xref rid="pone.0160517.ref024" ref-type="bibr">24</xref>].</p></sec><sec id="sec006"><title>RNA Data processing</title><p>The RNASeq data was processed as previously described [<xref rid="pone.0160517.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0160517.ref024" ref-type="bibr">24</xref>]. Concise details are in <xref ref-type="supplementary-material" rid="pone.0160517.s002">S2 file</xref>. Data was assessed using pairwise comparisons, correlation heatmaps and PCA plots and outliers removed accordingly. For RNASeq and smallSeq differentially expressed genes (DEGs) and transcripts were extracted by applying the threshold of false discovery rate (FDR) adjusted p-values &#x0003c; 0.05, generated using the Benjamini and Hochberg approach [<xref rid="pone.0160517.ref032" ref-type="bibr">32</xref>] and a 1.4 log<sub>2</sub> fold change (Log<sub>2</sub>FC). Sequence data have been submitted to National Centre for Biotechnology Information Gene Expression Omnibus (NCBI GEO) under Array Express accession number E-MTAB-3427.</p></sec><sec id="sec007"><title>Genomic DNA isolation, bisulphite treatment and methylation profiling</title><p>Genomic DNA was extracted using the SureSelect gDNA Extraction Kit (Agilent, Santa Clara, USA) according to manufacturer&#x02019;s instructions, 500 ng of genomic DNA was then bisulphite converted using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, USA). DNA methylation profiling of the samples was carried out by Cambridge Genomic Services (Cambridge, UK), using the Illumina Infinium HumanMethylation450 Beadchip array (Illumina, Inc., San Diego, USA).</p></sec><sec id="sec008"><title>Methylation data processing</title><p>GenomeStudio (Illumina Inc., San Diego,USA) was used to extract the raw data. GenomeStudio provides the methylation data as &#x003b2; values: &#x003b2; = M/(M + U) (M represents the fluorescent signal of the methylation probe; U represents the signal of the un-methylated probe). &#x003b2; values range from 0 (no methylation) to 1 (100% methylation). The raw methylation data was processed using R (version 3.0.1) and the Watermelon package (version 2.12) as has been previously described [<xref rid="pone.0160517.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0160517.ref033" ref-type="bibr">33</xref>]. Probes with a detection P value &#x0003e; 0.01 were removed. Age-related differential methylation was defined as Benjamini&#x02014;Hochberg corrected P value [<xref rid="pone.0160517.ref032" ref-type="bibr">32</xref>] &#x0003c; 0.01 or &#x0003c;0.05 (differentially methylated loci (DML) and gene/CpG island/promoter respectively) and a mean methylation difference (&#x00394; &#x003b2; score) &#x02265;0.15 (15%), as previously reported [<xref rid="pone.0160517.ref034" ref-type="bibr">34</xref>].</p></sec><sec id="sec009"><title>Functional analysis of transcriptomic and methylation data</title><p>To determine gene ontology, functional analyses, networks, canonical pathways and protein-protein interactions of age-related differentially expressed genes and methylated genes we performed analyses using Panther Classification System [<xref rid="pone.0160517.ref035" ref-type="bibr">35</xref>] and the functional analysis and clustering tool from the Database for Annotation, Visualisation, and Integrated Discovery (DAVID bioinformatics resources 6.7) [<xref rid="pone.0160517.ref036" ref-type="bibr">36</xref>] (using expressed genes as a reference), Ingenuity Pathway Analysis (IPA) [<xref rid="pone.0160517.ref037" ref-type="bibr">37</xref>]. Targetscan v6.2 was used to identify potential miR [<xref rid="pone.0160517.ref038" ref-type="bibr">38</xref>].</p></sec><sec id="sec010"><title>Relative gene expression using real-time polymerase chain reaction (<italic>qRT-PCR)</italic></title><p>qRT-PCR was undertaken on engineered tissues from similarly sourced MSCs at P4 from an independent cohort from those used for the RNA-Seq analysis young; n = 3 (22.2years&#x000b1;2.3SD) and old; n = 3 (64.8years&#x000b1;6.6SD). Primers were either validated in previous publications [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0160517.ref039" ref-type="bibr">39</xref>] and supplied by Eurogentec (Seraing, Belgium) or designed and validated commercially (Primer Design, Southampton, UK). Steady-state transcript abundance of potential endogenous control genes was measured in the RNA-Seq data. Assays for four genes&#x02014;Glutaraldehyde dehydrogenase (GAPDH), ribosomal protein 13 (RPS8), ribosomal protein 13 (RPS13), and ribosomal protein 16 (RPS16) were selected as potential reference genes as their expression was unaltered. Stability of this panel of genes was assessed by applying a gene stability algorithm [<xref rid="pone.0160517.ref040" ref-type="bibr">40</xref>]. RPS8 was selected as the most stable endogenous control gene. For miRs cDNA synthesis was performed using 100 ng RNA and miRscript RT kit II (Qiagen, Crawley, UK) according to the manufacturer&#x02019;s protocol. qRT-PCR analysis was performed using miRScript SybrGreen Mastermix (Qiagen, Crawley, UK) using Rnu-6 as the endogenous control. Relative expression levels were calculated by using the 2&#x02212;&#x00394;Ct method [<xref rid="pone.0160517.ref040" ref-type="bibr">40</xref>]. Data were analysed statistically using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) following normality testing using a Mann-Whitney test at a 0.05 level of significance.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Characterisation of engineered tissues</title><p>To evaluate chondrogenesis markers of chondrocytes were assessed; Alcian Blue staining for glycosaminoglycans and aggrecan gene expression. There was an increase in Alcian Blue staining and aggrecan (ACAN) expression (<xref ref-type="fig" rid="pone.0160517.g001">Fig 1A and 1B</xref>). Osteogenesis was evaluated with Alizarin Red staining. There was a significant increase in staining with Alizarin Red both visually and using quantitative analysis (<xref ref-type="fig" rid="pone.0160517.g001">Fig 1C and 1D</xref>) demonstrating osteogenesis. Tenogenic differentiation was evaluated histologically using Masson&#x02019;s Trichrome staining indicating areas of organised and disorganised collagen fibril formation within the tissues which were confirmed with TEM and gene expression of COL1A1 (<xref ref-type="fig" rid="pone.0160517.g001">Fig 1E and 1F</xref>), Serpin peptidase inhibitor F (SERPINF1) (<xref ref-type="fig" rid="pone.0160517.g001">Fig 1G</xref>) and thrombospondin 4 (THBS4) (<xref ref-type="fig" rid="pone.0160517.g001">Fig 1H</xref>) [<xref rid="pone.0160517.ref041" ref-type="bibr">41</xref>]. There were no age-related differences in the differentiation markers measured (data not shown).</p><fig id="pone.0160517.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g001</object-id><label>Fig 1</label><caption><title>Histochemical and gene expression analysis of chondrogenic, osteogenic and tenogenic lineage differentiation for MSCs.</title><p>Images are representative of all experiments. a; MSC pellets cultured in control or chondrogenic media were fixed and stained with Alcian Blue (scale bar 100&#x003bc;m, young donor shown) b;. Gene expression of aggrecan following chondrogenic differentiation, young and old donors combined. Data are represented as 2^-DCT compared with GAPDH. Box and whisker plots represent the median and 25&#x02013;75 percentiles. Statistical evaluation was undertaken using Mann Whitney-U test (n = 6). c; Osteogenic differentiation from MSCs was confirmed with Alizarin Red S staining at day 21 to visualize mineralized bone matrix following extraction of the calcified mineral from the stained monolayer at low pH (young donor shown). d; Box and whisker plot showing quantitative results of Alizarin red staining of all donors, statistical significance Mann-Whitney-U test p&#x0003c;0.001 (n = 12). e; Histology images of a tendon engineered tissue (young donor shown) made from MSCs stained with Masson&#x02019;s Trichrome to identify collagenous matrix. Image was captured at x4 magnification and x10 magnification inset (upper image); scale bar is 100&#x003bc;m. Example of more organised areas of collagen is marked on the inset image. Lower image depicts ultrastructural analysis using scanning transmission electron microscopy. The presence of aligned extracellular collagen fibrils (A) and less organised collagen (B) are inset in red; scale bar is 1&#x003bc;m. Tenogenic differentiation was also evaluated with using gene expression of f; COL1A1, g; SERPINF1 and h; THBS4. Data from all donors are represented as 2^-DCT compared with GAPDH. Statistical evaluation was undertaken using Mann Whitney-U test (n = 8).</p></caption><graphic xlink:href="pone.0160517.g001"/></fig></sec><sec id="sec013"><title>Overview of RNASeq and smallSeq data</title><p>For the RNASeq data an average of 68.53 million pairs of 100-bp paired-end reads per sample was generated that aligned to the human reference sequence. Based on data variation assessment one young and one old sample from chondrogenic were classed as outliers and removed from subsequent data analysis. Mapping results are summarised in the <xref ref-type="supplementary-material" rid="pone.0160517.s003">S3 file</xref>. Of the 63,152 human genes, between 39.9% and 47% had at least one read aligned [<xref rid="pone.0160517.ref042" ref-type="bibr">42</xref>]. This is similar to the output of other RNA-Seq studies [<xref rid="pone.0160517.ref043" ref-type="bibr">43</xref>]</p><p>In the smallSeq data an average of 12.2 million 50bp single-end reads was generated. This represented an average of 44% of reads mapped. Many of the 4206 human small RNAs were mapped with at least one read; 21.5&#x02013;38.5% within all samples. Mapping results are summarised in <xref ref-type="supplementary-material" rid="pone.0160517.s004">S4 file</xref> and are similar to other small RNASeq studies [<xref rid="pone.0160517.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0160517.ref045" ref-type="bibr">45</xref>]. Reads were used to estimate small RNA transcript expression of all samples using FPKM in order to identify the most abundant miRs and small nucleolar RNAs (snoRNAs). <xref ref-type="supplementary-material" rid="pone.0160517.s005">S5 file</xref> demonstrates the expression levels of the entire data set and highlights the top 10 highly expressed small RNAs genes within each class.</p></sec><sec id="sec014"><title>Identification of differentially expressed genes and differentially spliced genes using RNASeq</title><p>For RNASeq a principal component analysis (PCA) plot (<xref ref-type="fig" rid="pone.0160517.g002">Fig 2A</xref>) of log<sub>2</sub> gene expression data identified age-related biological variation within all engineered tissue groups. Hierarchical clustering using a sample to sample distance matrix identified clustering principally by engineered tissue type (<xref ref-type="fig" rid="pone.0160517.g002">Fig 2B</xref>).</p><fig id="pone.0160517.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g002</object-id><label>Fig 2</label><caption><p>(A) A PCA plot of RNASeq data revealed the greatest variability in RNASeq data was tissue type. (B) Correlation heatmap of RNASeq data from chondrogenic (chondro), osteogenic (osteo) and tenogenic (tendon) engineered tissues derived from young and old MSCs. Samples from same tissue are more closely correlated than sample from different tissue. (C) Venn diagram showing the DE genes from RNASeq for chondrogenic, osteogenic tenogenic engineered tissues (D) PCA plot of small RNASeq data. (E) Correlation heatmap of age-related DE small RNAs in chondrogenic (logFCchondro_Y vs O), osteogenic (logFCosteo_YvsO) and tenogenic (logFCtendon_YvsO) engineered tissues using small RNASeq. (F) Venn diagram depicting DE transcripts from RNASeq from differential splicing analysis for chondrogenic, osteogenic tenogenic engineered tissues. Hierarchical clustering of the samples revealed significant age-related changes in expression in osteogenic and tenogenic but not chondrogenic engineered tissues. Analysis was undertaken using the filters &#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0160517.g002"/></fig><p>Sets of age-related differentially expressed (DE) genes were identified including protein-coding RNA, long non-coding RNA (lnc), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), pseudogenes and miRs (<xref ref-type="table" rid="pone.0160517.t001">Table 1</xref>) (&#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05). There were 201, 67 and 32 chondrogenic, osteogenic and tenogenic age-related DE protein-coding genes respectively (<xref ref-type="fig" rid="pone.0160517.g002">Fig 2C</xref>). <xref ref-type="table" rid="pone.0160517.t002">Table 2</xref> represents the top 10 most differentially expressed up and down chondrogenic, osteogenic and tenogenic tissues. All DE genes are in <xref ref-type="supplementary-material" rid="pone.0160517.s006">S6 file</xref>. <xref ref-type="supplementary-material" rid="pone.0160517.s007">S7 file</xref> contains FPKM values for all samples, <xref ref-type="supplementary-material" rid="pone.0160517.s008">S8 file</xref> contains the MA plots for RNASeq and smallSeq.</p><table-wrap id="pone.0160517.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t001</object-id><label>Table 1</label><caption><title>Differentially expressed RNAs in chondrogenic, osteogenic and tenogenic engineered tissues based on RNA class (&#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05).</title></caption><alternatives><graphic id="pone.0160517.t001g" xlink:href="pone.0160517.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Engineered tissue Type</th><th align="center" rowspan="1" colspan="1">RNA class</th><th align="center" rowspan="1" colspan="1">Number differentially expressed</th><th align="center" rowspan="1" colspan="1">Number increased in old</th><th align="center" rowspan="1" colspan="1">Number reduced in old</th></tr></thead><tbody><tr><td align="center" rowspan="6" colspan="1"><bold>Chondrogenic</bold></td><td align="left" rowspan="1" colspan="1">protein coding</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">68</td></tr><tr><td align="left" rowspan="1" colspan="1">Inc</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">miR</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">snoRNA</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">snRNA</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">pseudogenes</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">22</td></tr><tr><td align="center" rowspan="2" colspan="1"><bold>Osteogenic</bold></td><td align="left" rowspan="1" colspan="1">protein coding</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="1" colspan="1">Inc</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="3" colspan="1"><bold>Tenogenic</bold></td><td align="left" rowspan="1" colspan="1">protein coding</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Inc</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">miR</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0160517.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t002</object-id><label>Table 2</label><caption><title>Protein-coding genes with the highest and lowest fold changes for each engineered tissue type.</title><p>A; chondrogenic, B; osteogenic, C: tenogenic.</p></caption><alternatives><graphic id="pone.0160517.t002g" xlink:href="pone.0160517.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="center" colspan="4" rowspan="1"><bold>A. chondrogenic</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gene Symbol</bold></td><td align="left" rowspan="1" colspan="1"><bold>Entrez Gene Name</bold></td><td align="left" rowspan="1" colspan="1"><bold>Fold Change</bold></td><td align="left" rowspan="1" colspan="1"><bold>FDR</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">NTF3</td><td align="left" rowspan="1" colspan="1">neurotrophin 3</td><td align="right" rowspan="1" colspan="1">8.61</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">SLPI</td><td align="left" rowspan="1" colspan="1">secretory leukocyte peptidase inhibitor</td><td align="right" rowspan="1" colspan="1">7.55</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">BEST2</td><td align="left" rowspan="1" colspan="1">bestrophin 2</td><td align="right" rowspan="1" colspan="1">7.4</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">CD14</td><td align="left" rowspan="1" colspan="1">CD14 molecule</td><td align="right" rowspan="1" colspan="1">6.97</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">ANKRD53</td><td align="left" rowspan="1" colspan="1">ankyrin repeat domain 53</td><td align="right" rowspan="1" colspan="1">5</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">IL18</td><td align="left" rowspan="1" colspan="1">interleukin 18</td><td align="right" rowspan="1" colspan="1">4.99</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">FBXO24</td><td align="left" rowspan="1" colspan="1">F-box protein 24</td><td align="right" rowspan="1" colspan="1">3.97</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">DAPK1</td><td align="left" rowspan="1" colspan="1">death-associated protein kinase 1</td><td align="right" rowspan="1" colspan="1">3.77</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC7A2</td><td align="left" rowspan="1" colspan="1">solute carrier family 7, member 2</td><td align="right" rowspan="1" colspan="1">3.62</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">ALX1</td><td align="left" rowspan="1" colspan="1">ALX homeobox 1</td><td align="right" rowspan="1" colspan="1">3.5</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC22A2</td><td align="left" rowspan="1" colspan="1">solute carrier family 22, member 2</td><td align="right" rowspan="1" colspan="1">-8.22</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="left" rowspan="1" colspan="1">mab-21-like 2</td><td align="right" rowspan="1" colspan="1">-8.13</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">KYNU</td><td align="left" rowspan="1" colspan="1">kynureninase</td><td align="right" rowspan="1" colspan="1">-7.98</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">UBE2QL1</td><td align="left" rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2Q family-like 1</td><td align="right" rowspan="1" colspan="1">-7.97</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">CA2</td><td align="left" rowspan="1" colspan="1">carbonic anhydrase II</td><td align="right" rowspan="1" colspan="1">-8.01</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">EBF2</td><td align="left" rowspan="1" colspan="1">early B-cell factor 2</td><td align="right" rowspan="1" colspan="1">-7.7</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">DLGAP1</td><td align="left" rowspan="1" colspan="1">discs, large homolog-associated protein 1</td><td align="right" rowspan="1" colspan="1">-7.62</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">PKHD1L1</td><td align="left" rowspan="1" colspan="1">polycystic kidney and hepatic disease 1 -like 1</td><td align="right" rowspan="1" colspan="1">-7.37</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">PCDHA7</td><td align="left" rowspan="1" colspan="1">protocadherin alpha 7</td><td align="right" rowspan="1" colspan="1">-7.32</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">IZUMO1</td><td align="left" rowspan="1" colspan="1">izumo sperm-egg fusion 1</td><td align="right" rowspan="1" colspan="1">-7.06</td><td align="right" rowspan="1" colspan="1">0.04</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>B. Osteogenic</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">ALX1</td><td align="left" rowspan="1" colspan="1">ALX homeobox 1</td><td align="right" rowspan="1" colspan="1">6.2</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">TGFA</td><td align="left" rowspan="1" colspan="1">transforming growth factor, alpha</td><td align="right" rowspan="1" colspan="1">6.18</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">HTR1F</td><td align="left" rowspan="1" colspan="1">5-hydroxytryptamine receptor 1F, G protein-coupled</td><td align="right" rowspan="1" colspan="1">5.14</td><td align="right" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">DDIT4L</td><td align="left" rowspan="1" colspan="1">DNA-damage-inducible transcript 4-like</td><td align="right" rowspan="1" colspan="1">5.39</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">MKRN3</td><td align="left" rowspan="1" colspan="1">makorin ring finger protein 3</td><td align="right" rowspan="1" colspan="1">4.32</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="left" rowspan="1" colspan="1">paired-like homeodomain 2</td><td align="right" rowspan="1" colspan="1">4.22</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">PDZRN4</td><td align="left" rowspan="1" colspan="1">PDZ domain containing ring finger 4</td><td align="right" rowspan="1" colspan="1">4.19</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">SPARCL1</td><td align="left" rowspan="1" colspan="1">SPARC-like 1 (hevin)</td><td align="right" rowspan="1" colspan="1">3.83</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">IL1RL1</td><td align="left" rowspan="1" colspan="1">interleukin 1 receptor-like 1</td><td align="right" rowspan="1" colspan="1">3.84</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">PRLR</td><td align="left" rowspan="1" colspan="1">prolactin receptor</td><td align="right" rowspan="1" colspan="1">4.11</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">EPHA7</td><td align="left" rowspan="1" colspan="1">EPH receptor A7</td><td align="right" rowspan="1" colspan="1">-7.36</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC6A15</td><td align="left" rowspan="1" colspan="1">solute carrier family 6, member 15</td><td align="right" rowspan="1" colspan="1">-7.34</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">IL13RA2</td><td align="left" rowspan="1" colspan="1">interleukin 13 receptor, alpha 2</td><td align="right" rowspan="1" colspan="1">-7.23</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="left" rowspan="1" colspan="1">mab-21-like 2</td><td align="right" rowspan="1" colspan="1">-6.46</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">THBD</td><td align="left" rowspan="1" colspan="1">thrombomodulin</td><td align="right" rowspan="1" colspan="1">-7</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">TNXB</td><td align="left" rowspan="1" colspan="1">tenascin XB</td><td align="right" rowspan="1" colspan="1">-6.89</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">NOVA1</td><td align="left" rowspan="1" colspan="1">neuro-oncological ventral antigen 1</td><td align="right" rowspan="1" colspan="1">-5.69</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">SULT1B1</td><td align="left" rowspan="1" colspan="1">sulfotransferase family, cytosolic, 1B, member 1</td><td align="right" rowspan="1" colspan="1">-5.57</td><td align="right" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">CNTNAP4</td><td align="left" rowspan="1" colspan="1">contactin associated protein-like 4</td><td align="right" rowspan="1" colspan="1">-5.25</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">DSG2</td><td align="left" rowspan="1" colspan="1">desmoglein 2</td><td align="right" rowspan="1" colspan="1">-5.31</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="center" colspan="4" rowspan="1"><bold>C. Tenogenic</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">ALX1</td><td align="left" rowspan="1" colspan="1">ALX homeobox 1</td><td align="right" rowspan="1" colspan="1">7.67</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">MKRN3</td><td align="left" rowspan="1" colspan="1">makorin ring finger protein 3</td><td align="right" rowspan="1" colspan="1">4.41</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="left" rowspan="1" colspan="1">homeobox B7</td><td align="right" rowspan="1" colspan="1">3.5</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB6</td><td align="left" rowspan="1" colspan="1">homeobox B6</td><td align="right" rowspan="1" colspan="1">3.24</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="left" rowspan="1" colspan="1">paired-like homeodomain 2</td><td align="right" rowspan="1" colspan="1">3.31</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">PLAT</td><td align="left" rowspan="1" colspan="1">plasminogen activator, tissue</td><td align="right" rowspan="1" colspan="1">2.68</td><td align="right" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">TNIK</td><td align="left" rowspan="1" colspan="1">TRAF2 and NCK interacting kinase</td><td align="right" rowspan="1" colspan="1">2.32</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXA3</td><td align="left" rowspan="1" colspan="1">homeobox A3</td><td align="right" rowspan="1" colspan="1">2.41</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">AHDC1</td><td align="left" rowspan="1" colspan="1">AT hook, DNA binding motif, containing 1</td><td align="right" rowspan="1" colspan="1">1.72</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">ZNF462</td><td align="left" rowspan="1" colspan="1">zinc finger protein 462</td><td align="right" rowspan="1" colspan="1">1.64</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="left" rowspan="1" colspan="1">mab-21-like 2</td><td align="right" rowspan="1" colspan="1">-6.85</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">NPTX1</td><td align="left" rowspan="1" colspan="1">neuronal pentraxin I</td><td align="right" rowspan="1" colspan="1">-6.79</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">THEGL</td><td align="left" rowspan="1" colspan="1">theg spermatid protein-like</td><td align="right" rowspan="1" colspan="1">-6.54</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">SRRM3</td><td align="left" rowspan="1" colspan="1">serine/arginine repetitive matrix 3</td><td align="right" rowspan="1" colspan="1">-5.07</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">MCF2L</td><td align="left" rowspan="1" colspan="1">MCF.2 cell line derived transforming sequence</td><td align="right" rowspan="1" colspan="1">-5.03</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">GPM6B</td><td align="left" rowspan="1" colspan="1">glycoprotein M6B</td><td align="right" rowspan="1" colspan="1">-4.89</td><td align="right" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">SYT16</td><td align="left" rowspan="1" colspan="1">synaptotagmin XVI</td><td align="right" rowspan="1" colspan="1">-4.88</td><td align="right" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">ELFN2</td><td align="left" rowspan="1" colspan="1">III domain containing 2</td><td align="right" rowspan="1" colspan="1">-4.76</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">HS3ST2</td><td align="left" rowspan="1" colspan="1">heparan sulfate 3-O-sulfotransferase 2</td><td align="right" rowspan="1" colspan="1">-4.75</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">EPHA7</td><td align="left" rowspan="1" colspan="1">EPH receptor A7</td><td align="right" rowspan="1" colspan="1">-4.18</td><td align="right" rowspan="1" colspan="1">0.03</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Log2 fold-change and false discovery rate (FDR) (adjusted P value) were determined in edgeR. A logarithm to the base 2 of 8 is a linear fold-change of 3. Shown are the 10 genes with highest and lowest expression in tissues derived from young compared to old MSCs. Negative LFC is higher in old.</p></fn></table-wrap-foot></table-wrap><p>In total 94190&#x000b1;3005 chondrogenic, 116105 &#x000b1;3008 osteogenic, and 113075&#x000b1;5346 tenogenic isoforms were detected (mean&#x000b1;standard deviation)). No isoforms were differentially expressed. However, using Cuffdiff to calculate changes in the relative splice abundances by quantifying the square root of the Jensen-Shannon divergence on primary transcripts with at least two isoforms, identified 119, 21 and 9 differential splicing events in chondrogenic, osteogenic and tenogenic tissues respectively (alternative splicing (AS)) (<xref ref-type="supplementary-material" rid="pone.0160517.s009">S9 file</xref>). These included small nucleolar RNAs, long non-coding RNAs and pseudogenes.</p><p>For the smallSeq PCA of log<sub>2</sub> gene expression data indicated the age-effect was weak (<xref ref-type="fig" rid="pone.0160517.g002">Fig 2D and 2E</xref>). The greatest variability was due to engineered tissue type. There were no age-related DE small RNAs in chondrogenic tissues. In osteogenic tissues, there were 36 DE miRs (all reduced were derived from old MSCs) and three DE snoRNAs and in tenogenic engineered tissues three miRs were DE (<xref ref-type="fig" rid="pone.0160517.g002">Fig 2F</xref>, <xref ref-type="table" rid="pone.0160517.t003">Table 3</xref>). The donor age-associated DE of several miRs in the osteogenic and tenogenic tissues was validated using qPCR (<xref ref-type="table" rid="pone.0160517.t004">Table 4</xref>). Validated miRs were chosen based on our own and published data with regards to the relevance to the osteogenic- and tenogenic-related processes.</p><table-wrap id="pone.0160517.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t003</object-id><label>Table 3</label><caption><title>Age-related differentially expressed small RNAs in osteogenic and tenogenic engineered tissues.</title></caption><alternatives><graphic id="pone.0160517.t003g" xlink:href="pone.0160517.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Tissue engineered type</th><th align="left" rowspan="1" colspan="1">Gene identification</th><th align="left" rowspan="1" colspan="1">Log fold change</th><th align="left" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="center" rowspan="39" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">miR-887-5p</td><td align="char" char="." rowspan="1" colspan="1">5.57</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-10a-3p</td><td align="char" char="." rowspan="1" colspan="1">4.07</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-369-3p</td><td align="char" char="." rowspan="1" colspan="1">3.48</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-651-5p</td><td align="char" char="." rowspan="1" colspan="1">3.47</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-542-3p</td><td align="char" char="." rowspan="1" colspan="1">3.27</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-450b-5p</td><td align="char" char="." rowspan="1" colspan="1">3.25</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-188-5p</td><td align="char" char="." rowspan="1" colspan="1">3.03</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-143-3p</td><td align="char" char="." rowspan="1" colspan="1">3.03</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1307-5p</td><td align="char" char="." rowspan="1" colspan="1">2.92</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-145-3p</td><td align="char" char="." rowspan="1" colspan="1">2.88</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-455-5p</td><td align="char" char="." rowspan="1" colspan="1">2.78</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-487a-3p</td><td align="char" char="." rowspan="1" colspan="1">2.70</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-376b-5p</td><td align="char" char="." rowspan="1" colspan="1">2.69</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-148a-3p</td><td align="char" char="." rowspan="1" colspan="1">2.67</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-450a-5p</td><td align="char" char="." rowspan="1" colspan="1">2.61</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-4775</td><td align="char" char="." rowspan="1" colspan="1">2.60</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-655-3p</td><td align="char" char="." rowspan="1" colspan="1">2.58</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-495-3p</td><td align="char" char="." rowspan="1" colspan="1">2.57</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1185-2-3p</td><td align="char" char="." rowspan="1" colspan="1">2.43</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-137</td><td align="char" char="." rowspan="1" colspan="1">2.42</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1185-1-3p</td><td align="char" char="." rowspan="1" colspan="1">2.27</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-136-3p</td><td align="char" char="." rowspan="1" colspan="1">2.24</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-340-5p</td><td align="char" char="." rowspan="1" colspan="1">2.22</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-30a-5p</td><td align="char" char="." rowspan="1" colspan="1">2.14</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-493-3p</td><td align="char" char="." rowspan="1" colspan="1">2.07</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-889-3p</td><td align="char" char="." rowspan="1" colspan="1">2.06</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-656-3p</td><td align="char" char="." rowspan="1" colspan="1">2.06</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">let-7i-3p</td><td align="char" char="." rowspan="1" colspan="1">2.00</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-382-3p</td><td align="char" char="." rowspan="1" colspan="1">2.00</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-140-5p</td><td align="char" char="." rowspan="1" colspan="1">1.97</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-370-3p</td><td align="char" char="." rowspan="1" colspan="1">1.97</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">let-7i-5p</td><td align="char" char="." rowspan="1" colspan="1">1.86</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-27b-3p</td><td align="char" char="." rowspan="1" colspan="1">1.83</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-98-5p</td><td align="char" char="." rowspan="1" colspan="1">1.82</td><td align="char" char="." rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-21-3p</td><td align="char" char="." rowspan="1" colspan="1">1.77</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-22-3p</td><td align="char" char="." rowspan="1" colspan="1">1.40</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">U44</td><td align="char" char="." rowspan="1" colspan="1">-1.56</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">SNORD65</td><td align="char" char="." rowspan="1" colspan="1">-1.69</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">SNORD126</td><td align="char" char="." rowspan="1" colspan="1">-1.79</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" rowspan="3" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">miR-500a-5p</td><td align="char" char="." rowspan="1" colspan="1">6.93</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-548j-5p</td><td align="char" char="." rowspan="1" colspan="1">6.40</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-618</td><td align="char" char="." rowspan="1" colspan="1">3.71</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>&#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0160517.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t004</object-id><label>Table 4</label><caption><title>The differential expression of several miRs was validated using qPCR.</title></caption><alternatives><graphic id="pone.0160517.t004g" xlink:href="pone.0160517.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">RNASeq</th><th align="left" colspan="6" rowspan="1">qPCR results</th></tr><tr><th align="left" rowspan="1" colspan="1">Engineered tissue type</th><th align="left" rowspan="1" colspan="1">microRNA</th><th align="left" rowspan="1" colspan="1">Log<sub>2</sub>FC</th><th align="left" rowspan="1" colspan="1">q-value</th><th align="left" rowspan="1" colspan="1">Young</th><th align="left" rowspan="1" colspan="1">Old</th><th align="left" rowspan="1" colspan="1">2^-&#x00394;CTlog<sub>2</sub>FC</th><th align="left" rowspan="1" colspan="1">p-value</th><th align="left" rowspan="1" colspan="1">SEM young</th><th align="left" rowspan="1" colspan="1">SEM old</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">let-7</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">0.38</td><td align="right" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">8.57</td><td align="right" rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">0.14</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-21</td><td align="left" rowspan="1" colspan="1">1.77</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="char" char="." rowspan="1" colspan="1">502.29</td><td align="right" rowspan="1" colspan="1">24.98</td><td align="char" char="." rowspan="1" colspan="1">4.33</td><td align="right" rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">169.65</td><td align="right" rowspan="1" colspan="1">14.09</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-30</td><td align="left" rowspan="1" colspan="1">2.14</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="char" char="." rowspan="1" colspan="1">8.77</td><td align="right" rowspan="1" colspan="1">0.18</td><td align="char" char="." rowspan="1" colspan="1">5.61</td><td align="right" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">2.11</td><td align="right" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-96</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="char" char="." rowspan="1" colspan="1">0.37</td><td align="right" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">8.53</td><td align="right" rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">0.16</td><td align="right" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-27</td><td align="left" rowspan="1" colspan="1">1.83</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">3.95</td><td align="right" rowspan="1" colspan="1">0.35</td><td align="char" char="." rowspan="1" colspan="1">3.50</td><td align="right" rowspan="1" colspan="1">0.05</td><td align="char" char="." rowspan="1" colspan="1">1.52</td><td align="right" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-140</td><td align="left" rowspan="1" colspan="1">1.97</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">1.64</td><td align="right" rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">5.77</td><td align="right" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.78</td><td align="right" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">miR-500</td><td align="left" rowspan="1" colspan="1">6.93</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">1.47</td><td align="right" rowspan="1" colspan="1">0.78</td><td align="char" char="." rowspan="1" colspan="1">0.91</td><td align="right" rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">0.18</td><td align="right" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">miR-548</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">1.09</td><td align="right" rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">5.77</td><td align="right" rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">0.55</td><td align="right" rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Relative expression levels were calculated by using the 2&#x02212;&#x00394;Ct method. Log2 fold-change of 2-&#x00394;Ct values are shown for comparison. NS; not significant</p></fn></table-wrap-foot></table-wrap><p>Reproducibility of RNASeq results with an independent platform is high [<xref rid="pone.0160517.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>]. Nevertheless we selected genes (mRNA and miRNA) DE and assessed their expression levels with qRT-PCR analyses for each engineered tissue type. There was good correlation between the deep sequencing analyses and qRT-PCR results (<xref ref-type="table" rid="pone.0160517.t005">Table 5</xref>) reflecting the accuracy and reliability of deep sequencing analyses.</p><table-wrap id="pone.0160517.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t005</object-id><label>Table 5</label><caption><title>Real-time polymerase chain reaction analysis of selected genes for each engineered tissue type revealed good correlation with RNA-Seq results.</title></caption><alternatives><graphic id="pone.0160517.t005g" xlink:href="pone.0160517.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="3" colspan="1">Engineered tissue type</th><th align="center" rowspan="3" colspan="1">Gene</th><th align="center" colspan="3" rowspan="2">RNA-Seq Results</th><th align="center" colspan="4" rowspan="1">RT-PCR Results</th></tr><tr><th align="center" colspan="2" rowspan="1">Age</th><th align="center" rowspan="2" colspan="1">2^<sup>-&#x00394;CT</sup>log<sub>2</sub>FC</th><th align="center" rowspan="2" colspan="1">p-value</th></tr><tr><th align="center" rowspan="1" colspan="1">Differential expression</th><th align="center" rowspan="1" colspan="1">Significant Log<sub>2</sub>FC</th><th align="center" rowspan="1" colspan="1">q-value</th><th align="center" rowspan="1" colspan="1">Young</th><th align="left" rowspan="1" colspan="1">Old</th></tr></thead><tbody><tr><td align="center" rowspan="5" colspan="1">Chondrogenic</td><td align="left" rowspan="1" colspan="1">ALX1</td><td align="center" rowspan="1" colspan="1">lower old</td><td align="center" rowspan="1" colspan="1">3.53</td><td align="right" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.11&#x000b1;0.05</td><td align="left" rowspan="1" colspan="1">0.63&#x000b1;0.48</td><td align="char" char="." rowspan="1" colspan="1">-2.52</td><td align="char" char="." rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">COL2A1</td><td align="center" rowspan="1" colspan="1">higher old</td><td align="center" rowspan="1" colspan="1">-6.74</td><td align="right" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.02&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.2&#x000b1;0.02</td><td align="char" char="." rowspan="1" colspan="1">-3.30</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAN</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">NA</td><td align="right" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">0.01&#x000b1;0.00</td><td align="left" rowspan="1" colspan="1">0.06&#x000b1;0.03</td><td align="char" char="." rowspan="1" colspan="1">-2.58</td><td align="char" char="." rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="center" rowspan="1" colspan="1">higher old</td><td align="center" rowspan="1" colspan="1">-3.84</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.01&#x000b1;0.00</td><td align="left" rowspan="1" colspan="1">0.47&#x000b1;0.33</td><td align="char" char="." rowspan="1" colspan="1">-5.55</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP16</td><td align="center" rowspan="1" colspan="1">higher old</td><td align="center" rowspan="1" colspan="1">-2.82</td><td align="right" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.00&#x000b1;0.00</td><td align="left" rowspan="1" colspan="1">0.52&#x000b1;0.51</td><td align="char" char="." rowspan="1" colspan="1">-9.02</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" rowspan="5" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">ALX1</td><td align="center" rowspan="5" colspan="1">lower old</td><td align="center" rowspan="1" colspan="1">6.26</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.01&#x000b1;0.04</td><td align="left" rowspan="1" colspan="1">0.4&#x000b1;0.06</td><td align="char" char="." rowspan="1" colspan="1">-5.32</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB6</td><td align="center" rowspan="1" colspan="1">3.38</td><td align="right" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.02&#x000b1;0.01</td><td align="char" char="." rowspan="1" colspan="1">2.81</td><td align="char" char="." rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.16</td><td align="left" rowspan="1" colspan="1">0.03&#x000b1;0.02</td><td align="char" char="." rowspan="1" colspan="1">3.37</td><td align="char" char="." rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.03&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.01&#x000b1;0.00</td><td align="char" char="." rowspan="1" colspan="1">1.58</td><td align="char" char="." rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">TGFA</td><td align="center" rowspan="1" colspan="1">5.64</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.42&#x000b1;0.28</td><td align="left" rowspan="1" colspan="1">0.02&#x000b1;0.01</td><td align="char" char="." rowspan="1" colspan="1">4.39</td><td align="char" char="." rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" rowspan="4" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">ALX1</td><td align="center" rowspan="4" colspan="1">lower old</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">164.67&#x000b1;29.02</td><td align="left" rowspan="1" colspan="1">0.26&#x000b1;0.11</td><td align="char" char="." rowspan="1" colspan="1">9.31</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB6</td><td align="center" rowspan="1" colspan="1">3.66</td><td align="right" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">53.04&#x000b1;9.00</td><td align="left" rowspan="1" colspan="1">0.18&#x000b1;0.10</td><td align="char" char="." rowspan="1" colspan="1">8.20</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="center" rowspan="1" colspan="1">3.77</td><td align="right" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">55.2&#x000b1;10.1</td><td align="left" rowspan="1" colspan="1">0.25&#x000b1;0.10</td><td align="char" char="." rowspan="1" colspan="1">7.79</td><td align="char" char="." rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="center" rowspan="1" colspan="1">3.51</td><td align="right" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">22.68&#x000b1;2.85</td><td align="left" rowspan="1" colspan="1">0.32&#x000b1;0.12</td><td align="char" char="." rowspan="1" colspan="1">6.15</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>Values for quantitative real-time polymerase chain reaction (qRT-PCR) are the mean &#x000b1; standard error of relative expression levels normalised to expression of RPS8 (to two decimal places). Statistical significance was tested by using Mann-Whitney U test. q RT-PCR results are expressed as 2-&#x00394;Ct. Log2 fold-change of 2-&#x00394;Ct values are shown for comparison. ALX1; ALX homeobox 1, ACAN, aggrecan; COL2A1, collagen type 2 alpha 1; HOXB6; homeobox B6, HOXB7; homeobox B7, MAB21L2; MAB21-like 2, PITX2; paired-like homeodomain transcription factor 2, MMP16, matrix metalloproteinase 16; TGFA; transforming growth factor alpha. NS; not significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec015"><title>Gene ontology (GO) and IPA analysis of DEGs and AS genes</title><p>For each engineered tissue type age-related DEGs (adjusted P&#x0003c;0.05 and 1.4 log<sub>2</sub> fold change) were analysed in DAVID. Significant annotations included shared terms &#x02018;glycoprotein&#x02019; and &#x02018;extracellular matrix&#x02019; (ECM) for chondrogenic and osteogenic. In addition the terms &#x02018;growth factor&#x02019; and &#x02018;secreted&#x02019; were identified for chondrogenic and osteogenic respectively. For tenogenic &#x02018;developmental protein&#x02019; and &#x02018;homeobox&#x02019; were significantly enriched. The DEGs were next input into IPA. This inferred the nature of the engineered tissue protein-coding transcript networks was predominantly for the functions &#x02018;cell death and survival&#x02019;, &#x02018;cell morphology&#x02019;, and &#x02018;cell growth and proliferation&#x02019;. The canonical pathways significantly identified from the gene sets are shown in <xref ref-type="table" rid="pone.0160517.t006">Table 6</xref>. The top networks identified for each engineered tissue type were &#x02018;developmental disorders, hereditary disorders and metabolic disease&#x02019; for chondrogenic (<xref ref-type="fig" rid="pone.0160517.g003">Fig 3A</xref>); &#x02018;cellular growth and proliferation, cell development&#x02019; and &#x02018;morphology&#x02019; for osteogenic (<xref ref-type="fig" rid="pone.0160517.g003">Fig 3B</xref>); and &#x02018;embryonic and organismal development&#x02019; for tenogenic (<xref ref-type="fig" rid="pone.0160517.g003">Fig 3C</xref>).</p><fig id="pone.0160517.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g003</object-id><label>Fig 3</label><caption><title>Top scoring networks.</title><p>Networks derived from the DE genes with age-related different abundance identified the top network for each chondrogenic, osteogenic and tenogenic tissues with scores of 44, 41, and 42 respectively. These related to developmental disorders, hereditary disorders and metabolic disease for chondrogenic (A), cellular growth and proliferation, cell development and morphology for osteogenic (B) and embryonic and organismal development for tenogenic (C). Green nodes, increased expression in old; red nodes, lower expression in old; white nodes, genes not differentially expressed with age. Intensity of colour is related to higher fold-change. Legend to the main features in the networks is shown. Significant functions related to chondrogenic included mitochondrial disorders (p = 5.2e<sup>-29</sup>) and mitochondrial respiratory chain deficiency (p = 1.6e<sup>-17</sup>), for osteogenic include differentiation of cells (p = 4.5e<sup>-5</sup>) and for tenogenic include differentiation of connective tissue cells (p = 9.5e<sup>-5</sup>). These are highlighted in purple.</p></caption><graphic xlink:href="pone.0160517.g003"/></fig><table-wrap id="pone.0160517.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t006</object-id><label>Table 6</label><caption><title>The top canonical pathways.</title><p>Pathways from the IPA knowledge base that involve DE (adjusted P&#x0003c;0.05 and 1.4 log<sub>2</sub> fold change) protein coding genes differentially expressed in tissues derived from young compared to old MSCs; chondrogenic, tenogenic and osteogenic.</p></caption><alternatives><graphic id="pone.0160517.t006g" xlink:href="pone.0160517.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Engineered tissue type</th><th align="left" rowspan="1" colspan="1">Ingenuity Canonical Pathways</th><th align="left" rowspan="1" colspan="1">-log(p-value)</th><th align="left" rowspan="1" colspan="1">Ratio</th></tr></thead><tbody><tr><td align="center" rowspan="5" colspan="1">Chondrogenic</td><td align="left" rowspan="1" colspan="1">Mitochondrial Dysfunction</td><td align="right" rowspan="1" colspan="1">1.01E+01</td><td align="right" rowspan="1" colspan="1">7.94E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Oxidative Phosphorylation</td><td align="right" rowspan="1" colspan="1">9.37E+00</td><td align="right" rowspan="1" colspan="1">1.00E-01</td></tr><tr><td align="left" rowspan="1" colspan="1">GDNF Family Ligand-Receptor Interactions</td><td align="right" rowspan="1" colspan="1">3.48E+00</td><td align="right" rowspan="1" colspan="1">7.04E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic Fibrosis / Hepatic Stellate Cell Activation</td><td align="right" rowspan="1" colspan="1">2.14E+00</td><td align="right" rowspan="1" colspan="1">2.99E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Tryptophan Degradation</td><td align="right" rowspan="1" colspan="1">2.00E+00</td><td align="right" rowspan="1" colspan="1">1.11E-01</td></tr><tr><td align="center" rowspan="5" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">IL-12 Signalling and Production in Macrophages</td><td align="right" rowspan="1" colspan="1">3.08E+00</td><td align="right" rowspan="1" colspan="1">2.88E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">VDR/RXR Activation</td><td align="right" rowspan="1" colspan="1">2.76E+00</td><td align="right" rowspan="1" colspan="1">3.80E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic Cholestasis</td><td align="right" rowspan="1" colspan="1">2.70E+00</td><td align="right" rowspan="1" colspan="1">2.26E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic Fibrosis / Hepatic Stellate Cell Activation</td><td align="right" rowspan="1" colspan="1">2.50E+00</td><td align="right" rowspan="1" colspan="1">1.99E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreatic Adenocarcinoma Signalling</td><td align="right" rowspan="1" colspan="1">2.37E+00</td><td align="right" rowspan="1" colspan="1">2.78E-02</td></tr><tr><td align="center" rowspan="5" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">PPAR Signalling</td><td align="right" rowspan="1" colspan="1">3.38E+00</td><td align="right" rowspan="1" colspan="1">3.19E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS/IL-1 Mediated Inhibition of RXR Function</td><td align="right" rowspan="1" colspan="1">2.33E+00</td><td align="right" rowspan="1" colspan="1">1.38E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6 Signalling</td><td align="right" rowspan="1" colspan="1">1.85E+00</td><td align="right" rowspan="1" colspan="1">1.72E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Type II Diabetes Mellitus Signalling</td><td align="right" rowspan="1" colspan="1">1.85E+00</td><td align="right" rowspan="1" colspan="1">1.71E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">HMGB1 Signalling</td><td align="right" rowspan="1" colspan="1">1.83E+00</td><td align="right" rowspan="1" colspan="1">1.67E-02</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t006fn001"><p>The -log(p-values) were calculated by Fisher's exact test right-tailed.</p></fn></table-wrap-foot></table-wrap><p>GO analyses using PANTHER indicated enrichment in genes associated principally with metabolic processes in all engineered tissue type genes undergoing AS (<xref ref-type="fig" rid="pone.0160517.g004">Fig 4A</xref>). The chondrogenic and tenogenic AS gene sets was then analysed with IPA. For chondrogenic tissues the top pathways identified included cell death and survival (p = -2.96E-02- 5.42E-05), cellular compromise (p = 2.54E-02-5.42E-05), organismal survival (p = 2.96E-02-5.35E-04) and tissue development (p = 2.54E-02-6.04E-04). The top network identified was cell death, survival, cellular compromise, connective tissue disorders with a score of 40. <xref ref-type="fig" rid="pone.0160517.g004">Fig 4B</xref> shows this network with some significant functions overlaid; connective tissue (p = 2.48E-08) and proliferation of connective tissue (p = 6.77E-07). For tenogenic top pathways identified included carbohydrate metabolism (p = 1.73E-02-7.29E-04), lipid metabolism (p = 2.95E-02-7.29E-04), cellular function and maintenance (p = 3.65E02-7.29E-04) and connective tissue development and function (p = 3.3E-02-7.29E-04). The principal network involved cell to cell signalling and interaction, cell morphology, function and maintenance (score 36) (<xref ref-type="fig" rid="pone.0160517.g004">Fig 4C</xref>).</p><fig id="pone.0160517.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g004</object-id><label>Fig 4</label><caption><title>Bioinformatics analysis of AS in engineered tissues.</title><p>A. Pie charts depicting biological process gene ontology of DE genes in ageing using PANTHER. Genes were demonstrated as DE with &#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05. B. The top scoring IPA derived network for significant AS genes in chondrogenic tissues. This related to&#x02019; cell death and survival, cellular compromise and connective tissue disorders&#x02019;. Significant functions related to the network are overlaid; growth of connective tissue (p = 2.48E-08) and proliferation of connective tissue (p = 6.77E-07). C. The top scoring IPA derived network for significant AS genes in tenogenic tissues was &#x02018;cell to cell signalling and interaction, cell morphology, function and maintenance&#x02019;. Key to the main features in the networks is shown. Grey nodes were those identified as significant from the AS gene dataset, white nodes genes not in dataset.</p></caption><graphic xlink:href="pone.0160517.g004"/></fig></sec><sec id="sec016"><title>Gene pairing analysis of DE miRs and DE RNAs</title><p>The expression patterns of DE miRs and mRNA were further analysed using IPA by investigating opposite fold-change direction (up/down or down/up), following the canonical miR-mRNA target expression paradigm with moderate to high confidence. Potentially relevant miR-mRNA signatures involved in the age-related changes were identified; 16 for osteogenic and one for tenogenic (<xref ref-type="supplementary-material" rid="pone.0160517.s010">S10 file</xref>). Using PANTHER the mRNA in which related miRs were identified in osteogenic tissues were enriched in the cellular components ECM (52% of genes) and enriched for the functions &#x02018;binding (44%).</p></sec><sec id="sec017"><title>Comparison of the DNA methylome in ageing MSCs</title><p>Unsupervised hierarchical clustering revealed that young and old samples are distinguished by their DNA methylome in all engineered tissue types (<xref ref-type="fig" rid="pone.0160517.g005">Fig 5</xref>). Technical triplicate replicates were included for a single donor for chondrogenic and osteogenic young donors and correlation was excellent. Significant age-related differentially methylated loci (DML), both tissue specific and common CpGs, were identified in all engineered tissue types (<xref ref-type="table" rid="pone.0160517.t007">Table 7</xref>). <xref ref-type="supplementary-material" rid="pone.0160517.s011">S11 file</xref> contains all DML for each engineered tissue type and <xref ref-type="supplementary-material" rid="pone.0160517.s012">S12 file</xref> identifies these at the site, promoter, gene and CpG island level. In all engineered tissue groups and regions hypomethylation in old samples was dominant.</p><fig id="pone.0160517.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g005</object-id><label>Fig 5</label><caption><title>Heatmap showing the unsupervised clustering of the DMLs between the young (n = 4) and old (n = 4) chondrogenic (A), osteogenic (B) and tenogenic (B) engineered tissues.</title><p>For chondrogenic young and osteogenic young a sample was run in triplicate technical replicates. DMLs were defined as at least a 10% difference in methylation between the two groups, and an FDR-corrected P value of &#x0003c;0.05. The dendogram at the top shows the clustering of the samples and the dendogram to the side show clustering of the loci. The methylation scale is shown at the left of the heatmap (1 = 100% methylation, 0 = no methylation).</p></caption><graphic xlink:href="pone.0160517.g005"/></fig><table-wrap id="pone.0160517.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t007</object-id><label>Table 7</label><caption><title>Number of age-related differentially methylated loci (DML), genes, CpG islands and promoters.</title></caption><alternatives><graphic id="pone.0160517.t007g" xlink:href="pone.0160517.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Engineered tissue type</th><th align="left" rowspan="1" colspan="1">Region</th><th align="left" rowspan="1" colspan="1">Total number DE</th><th align="center" rowspan="1" colspan="1">Number hypomethylated in old</th><th align="left" rowspan="1" colspan="1">Number hypermethylated in old</th></tr></thead><tbody><tr><td align="center" rowspan="4" colspan="1">Chondrogenic</td><td align="left" rowspan="1" colspan="1">DML</td><td align="right" rowspan="1" colspan="1">609</td><td align="right" rowspan="1" colspan="1">402</td><td align="right" rowspan="1" colspan="1">207</td></tr><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="right" rowspan="1" colspan="1">12</td><td align="right" rowspan="1" colspan="1">7</td><td align="right" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">CpG Island</td><td align="right" rowspan="1" colspan="1">58</td><td align="right" rowspan="1" colspan="1">43</td><td align="right" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">Promoter</td><td align="right" rowspan="1" colspan="1">17</td><td align="right" rowspan="1" colspan="1">12</td><td align="right" rowspan="1" colspan="1">5</td></tr><tr><td align="center" rowspan="4" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">DML</td><td align="right" rowspan="1" colspan="1">507</td><td align="right" rowspan="1" colspan="1">367</td><td align="right" rowspan="1" colspan="1">140</td></tr><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="right" rowspan="1" colspan="1">11</td><td align="right" rowspan="1" colspan="1">8</td><td align="right" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">CpG Island</td><td align="right" rowspan="1" colspan="1">38</td><td align="right" rowspan="1" colspan="1">32</td><td align="right" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Promoter</td><td align="right" rowspan="1" colspan="1">15</td><td align="right" rowspan="1" colspan="1">12</td><td align="right" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="4" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">DML</td><td align="right" rowspan="1" colspan="1">157</td><td align="right" rowspan="1" colspan="1">122</td><td align="right" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">0</td><td align="right" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">CpG Island</td><td align="right" rowspan="1" colspan="1">314</td><td align="right" rowspan="1" colspan="1">300</td><td align="right" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">Promoter</td><td align="right" rowspan="1" colspan="1">30</td><td align="right" rowspan="1" colspan="1">27</td><td align="right" rowspan="1" colspan="1">3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t007fn001"><p>Significance was defined as Benjamini&#x02014;Hochberg corrected P value &#x0003c; 0.01 (DML) or &#x0003c;0.05 (gene, CpG island, promoter) and a mean methylation difference (&#x00394; &#x003b2; score) &#x02265;0.15.</p></fn></table-wrap-foot></table-wrap><p>Gene ontology analysis of genes containing DML indicated age-related enrichment for all engineered tissue types in skeletal system morphogenesis, regulation of cell proliferation and regulation of transcription.</p><p>To identify the canonical pathways, biological function, and networks that were affected by the differentially methylated genes, we used IPA analysis. Results suggest that dynamic epigenetic modifications may occur in genes associated with a number of shared and distinct pathways dependent upon engineered tissue type. The top 10 genes with increased and decreased methylation levels based on Beta values (methylation difference) are listed in <xref ref-type="table" rid="pone.0160517.t008">Table 8</xref>.</p><table-wrap id="pone.0160517.t008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t008</object-id><label>Table 8</label><caption><title>Top 10 annotated genes with increased and decreased methylation.</title></caption><alternatives><graphic id="pone.0160517.t008g" xlink:href="pone.0160517.t008"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Engineered tissue type</th><th align="left" rowspan="1" colspan="1">Symbol</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="left" rowspan="1" colspan="1">Beta</th><th align="left" rowspan="1" colspan="1">Location</th><th align="left" rowspan="1" colspan="1">Type(s)</th></tr></thead><tbody><tr><td align="center" rowspan="20" colspan="1">chondrogenic</td><td align="left" rowspan="1" colspan="1">HOXA5</td><td align="left" rowspan="1" colspan="1">homeobox A5</td><td align="char" char="." rowspan="1" colspan="1">-0.67</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">HAND2</td><td align="left" rowspan="1" colspan="1">heart and neural crest derivatives expressed 2</td><td align="char" char="." rowspan="1" colspan="1">-0.66</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">mir-548</td><td align="left" rowspan="1" colspan="1">microRNA 548c</td><td align="char" char="." rowspan="1" colspan="1">-0.63</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" rowspan="1" colspan="1">SMTNL1</td><td align="left" rowspan="1" colspan="1">smoothelin-like 1</td><td align="char" char="." rowspan="1" colspan="1">-0.60</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMA1</td><td align="left" rowspan="1" colspan="1">laminin, alpha 1</td><td align="char" char="." rowspan="1" colspan="1">-0.60</td><td align="left" rowspan="1" colspan="1">Extracellular Space</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">SHANK2</td><td align="left" rowspan="1" colspan="1">SH3 and multiple ankyrin repeat domains 2</td><td align="char" char="." rowspan="1" colspan="1">-0.58</td><td align="left" rowspan="1" colspan="1">Plasma Membrane</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2</td><td align="left" rowspan="1" colspan="1">empty spiracles homeobox 2</td><td align="char" char="." rowspan="1" colspan="1">-0.57</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">GAPT</td><td align="left" rowspan="1" colspan="1">GRB2-binding adaptor protein, transmembrane</td><td align="char" char="." rowspan="1" colspan="1">-0.57</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">USP28</td><td align="left" rowspan="1" colspan="1">ubiquitin specific peptidase 28</td><td align="char" char="." rowspan="1" colspan="1">-0.57</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">peptidase</td></tr><tr><td align="left" rowspan="1" colspan="1">SAMD12</td><td align="left" rowspan="1" colspan="1">sterile alpha motif domain containing 12</td><td align="char" char="." rowspan="1" colspan="1">-0.53</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC12A7</td><td align="left" rowspan="1" colspan="1">solute carrier family 12, member 7</td><td align="char" char="." rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">Plasma Membrane</td><td align="left" rowspan="1" colspan="1">transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">LRBA</td><td align="left" rowspan="1" colspan="1">LPS-responsive vesicle trafficking</td><td align="char" char="." rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB4</td><td align="left" rowspan="1" colspan="1">homeobox B4</td><td align="char" char="." rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">RUNX3</td><td align="left" rowspan="1" colspan="1">runt-related transcription factor 3</td><td align="char" char="." rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="left" rowspan="1" colspan="1">paired-like homeodomain 2</td><td align="char" char="." rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXA11-AS</td><td align="left" rowspan="1" colspan="1">HOXA11 antisense RNA</td><td align="char" char="." rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">mir-10</td><td align="left" rowspan="1" colspan="1">microRNA 100</td><td align="char" char="." rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="left" rowspan="1" colspan="1">homeobox B7</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2OS</td><td align="left" rowspan="1" colspan="1">EMX2 opposite strand/antisense RNA</td><td align="char" char="." rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX15</td><td align="left" rowspan="1" colspan="1">T-box 15</td><td align="char" char="." rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="21" colspan="1">osteogenic</td><td align="left" rowspan="1" colspan="1">HOXA5</td><td align="left" rowspan="1" colspan="1">homeobox A5</td><td align="char" char="." rowspan="1" colspan="1">-0.77</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXA2</td><td align="left" rowspan="1" colspan="1">homeobox A2</td><td align="char" char="." rowspan="1" colspan="1">-0.76</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMA1</td><td align="left" rowspan="1" colspan="1">laminin, alpha 1</td><td align="char" char="." rowspan="1" colspan="1">-0.69</td><td align="left" rowspan="1" colspan="1">Extracellular Space</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">PARP4</td><td align="left" rowspan="1" colspan="1">poly (ADP-ribose) polymerase family, member 4</td><td align="char" char="." rowspan="1" colspan="1">-0.67</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">enzyme</td></tr><tr><td align="left" rowspan="1" colspan="1">SIX2</td><td align="left" rowspan="1" colspan="1">SIX homeobox 2</td><td align="char" char="." rowspan="1" colspan="1">-0.65</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">PRRX1</td><td align="left" rowspan="1" colspan="1">paired related homeobox 1</td><td align="char" char="." rowspan="1" colspan="1">-0.62</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">CPNE4</td><td align="left" rowspan="1" colspan="1">copine IV</td><td align="char" char="." rowspan="1" colspan="1">-0.62</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">GAPT</td><td align="left" rowspan="1" colspan="1">GRB2-binding adaptor protein, transmembrane</td><td align="char" char="." rowspan="1" colspan="1">-0.62</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">MIR548F5</td><td align="left" rowspan="1" colspan="1">microRNA 548c</td><td align="char" char="." rowspan="1" colspan="1">-0.61</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" rowspan="1" colspan="1">USP28</td><td align="left" rowspan="1" colspan="1">ubiquitin specific peptidase 28</td><td align="char" char="." rowspan="1" colspan="1">-0.58</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">peptidase</td></tr><tr><td align="left" rowspan="1" colspan="1">BMX</td><td align="left" rowspan="1" colspan="1">BMX non-receptor tyrosine kinase</td><td align="char" char="." rowspan="1" colspan="1">0.57</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">kinase</td></tr><tr><td align="left" rowspan="1" colspan="1">DMRT2</td><td align="left" rowspan="1" colspan="1">doublesex and mab-3 related transcription factor 2</td><td align="char" char="." rowspan="1" colspan="1">0.57</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX18</td><td align="left" rowspan="1" colspan="1">T-box 18</td><td align="char" char="." rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">EPB41L5</td><td align="left" rowspan="1" colspan="1">erythrocyte membrane protein band 4.1 like 5</td><td align="char" char="." rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">Plasma Membrane</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC12A7</td><td align="left" rowspan="1" colspan="1">solute carrier family 12, member 7</td><td align="char" char="." rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">Plasma Membrane</td><td align="left" rowspan="1" colspan="1">transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="left" rowspan="1" colspan="1">homeobox B7</td><td align="char" char="." rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXA11AS</td><td align="left" rowspan="1" colspan="1">HOXA11 antisense RNA</td><td align="char" char="." rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">MIR10A</td><td align="left" rowspan="1" colspan="1">microRNA 100</td><td align="char" char="." rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2OS</td><td align="left" rowspan="1" colspan="1">EMX2 opposite strand/antisense RNA</td><td align="char" char="." rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="left" rowspan="1" colspan="1">paired-like homeodomain 2</td><td align="char" char="." rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX15</td><td align="left" rowspan="1" colspan="1">T-box 15</td><td align="char" char="." rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="center" rowspan="20" colspan="1">tenogenic</td><td align="left" rowspan="1" colspan="1">HOXA5</td><td align="left" rowspan="1" colspan="1">homeobox A5</td><td align="char" char="." rowspan="1" colspan="1">-0.74</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMA1</td><td align="left" rowspan="1" colspan="1">laminin, alpha 1</td><td align="char" char="." rowspan="1" colspan="1">-0.69</td><td align="left" rowspan="1" colspan="1">Extracellular Space</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXA3</td><td align="left" rowspan="1" colspan="1">homeobox A3</td><td align="char" char="." rowspan="1" colspan="1">-0.69</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">PARP4</td><td align="left" rowspan="1" colspan="1">poly (ADP-ribose) polymerase family, member 4</td><td align="char" char="." rowspan="1" colspan="1">-0.65</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">enzyme</td></tr><tr><td align="left" rowspan="1" colspan="1">PRRX1</td><td align="left" rowspan="1" colspan="1">paired related homeobox 1</td><td align="char" char="." rowspan="1" colspan="1">-0.59</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">CPNE4</td><td align="left" rowspan="1" colspan="1">copine IV</td><td align="char" char="." rowspan="1" colspan="1">-0.57</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB2</td><td align="left" rowspan="1" colspan="1">homeobox B2</td><td align="char" char="." rowspan="1" colspan="1">-0.50</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2</td><td align="left" rowspan="1" colspan="1">empty spiracles homeobox 2</td><td align="char" char="." rowspan="1" colspan="1">-0.49</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">PHACTR1</td><td align="left" rowspan="1" colspan="1">phosphatase and actin regulator 1</td><td align="char" char="." rowspan="1" colspan="1">-0.46</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">GRIK3</td><td align="left" rowspan="1" colspan="1">glutamate receptor, ionotropic, kainate 3</td><td align="char" char="." rowspan="1" colspan="1">-0.45</td><td align="left" rowspan="1" colspan="1">Plasma Membrane</td><td align="left" rowspan="1" colspan="1">ion channel</td></tr><tr><td align="left" rowspan="1" colspan="1">KHDRBS3</td><td align="left" rowspan="1" colspan="1">KH domain containing, signal transduction associated 3</td><td align="char" char="." rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">BMX</td><td align="left" rowspan="1" colspan="1">BMX non-receptor tyrosine kinase</td><td align="char" char="." rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">kinase</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB4</td><td align="left" rowspan="1" colspan="1">homeobox B4</td><td align="char" char="." rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">RUNX3</td><td align="left" rowspan="1" colspan="1">runt-related transcription factor 3</td><td align="char" char="." rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX5</td><td align="left" rowspan="1" colspan="1">T-box 5</td><td align="char" char="." rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">LRBA</td><td align="left" rowspan="1" colspan="1">LPS-responsive vesicle trafficking</td><td align="char" char="." rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">Cytoplasm</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">mir-10</td><td align="left" rowspan="1" colspan="1">microRNA 100</td><td align="char" char="." rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2OS</td><td align="left" rowspan="1" colspan="1">EMX2 opposite strand/antisense RNA</td><td align="char" char="." rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">other</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="left" rowspan="1" colspan="1">paired-like homeodomain 2</td><td align="char" char="." rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX15</td><td align="left" rowspan="1" colspan="1">T-box 15</td><td align="char" char="." rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">Nucleus</td><td align="left" rowspan="1" colspan="1">transcription regulator</td></tr></tbody></table></alternatives></table-wrap><p>Canonical pathways were analysed based on the ratio of input genes to the total number of reference genes in the corresponding pathways in the IPA knowledge bases. Fisher&#x02019;s exact test was employed to calculate the P values to determine significant associations between the DM genes and the canonical pathways. The top five canonical pathways for each engineered tissue type are in <xref ref-type="table" rid="pone.0160517.t009">Table 9</xref>. Then we used IPA comparison analysis to visualise downstream effects analysis results across each engineered tissue type simultaneously. This identified diseases and biological functions predicted to increase or decrease related to age-affected DML through functional scores (<xref ref-type="fig" rid="pone.0160517.g006">Fig 6A</xref>). Interestingly in all engineered tissue types the function &#x02018;differentiation of cells&#x02019; was activated (<xref ref-type="fig" rid="pone.0160517.g006">Fig 6B</xref>) whereas the &#x02018;cell survival&#x02019; network was only affected in chondrogenic and osteogenic tissues. The network &#x02018;congenital anomalies of the musculoskeletal system&#x02019; was activated in tenogenic but inhibited in chondrogenic and osteogenic. The most significant network for each engineered tissue was &#x02018;skeletal and muscular development and function&#x02019;.</p><table-wrap id="pone.0160517.t009" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t009</object-id><label>Table 9</label><caption><title>The five significant canonical pathways related to changes in the methylation patterns for each tissues type.</title><p>The log (p-value) of each pathway was determined using Fisher&#x02019;s exact test. The ratios were calculated as the number of input molecules mapped to a specific pathway divided by the total number of molecules in the given pathway.</p></caption><alternatives><graphic id="pone.0160517.t009g" xlink:href="pone.0160517.t009"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Engineered tissue Type</th><th align="left" rowspan="1" colspan="1">Ingenuity Canonical Pathways</th><th align="left" rowspan="1" colspan="1">-log(p-value)</th><th align="left" rowspan="1" colspan="1">Ratio</th></tr></thead><tbody><tr><td align="center" rowspan="5" colspan="1">Chondrogenic</td><td align="left" rowspan="1" colspan="1">Hepatic Fibrosis</td><td align="right" rowspan="1" colspan="1">5.62E+00</td><td align="right" rowspan="1" colspan="1">8.96E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">mTOR Signalling</td><td align="right" rowspan="1" colspan="1">4.61E+00</td><td align="right" rowspan="1" colspan="1">8.25E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Tight Junction Signalling</td><td align="right" rowspan="1" colspan="1">4.19E+00</td><td align="right" rowspan="1" colspan="1">8.38E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic Myeloid Leukemia Signalling</td><td align="right" rowspan="1" colspan="1">4.03E+00</td><td align="right" rowspan="1" colspan="1">1.08E-01</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-9 Signalling</td><td align="right" rowspan="1" colspan="1">3.80E+00</td><td align="right" rowspan="1" colspan="1">1.76E-01</td></tr><tr><td align="center" rowspan="5" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">AMPK Signaling</td><td align="right" rowspan="1" colspan="1">3.49E+00</td><td align="right" rowspan="1" colspan="1">6.63E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropathic Pain Signalling In Dorsal Horn Neurons</td><td align="right" rowspan="1" colspan="1">3.40E+00</td><td align="right" rowspan="1" colspan="1">8.65E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">VEGF Family Ligand-Receptor Interactions</td><td align="right" rowspan="1" colspan="1">2.73E+00</td><td align="right" rowspan="1" colspan="1">8.54E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Glutamate Receptor Signalling</td><td align="right" rowspan="1" colspan="1">2.61E+00</td><td align="right" rowspan="1" colspan="1">9.38E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Human Embryonic Stem Cell Pluripotency</td><td align="right" rowspan="1" colspan="1">2.51E+00</td><td align="right" rowspan="1" colspan="1">6.47E-02</td></tr><tr><td align="center" rowspan="5" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">TGFB Signalling</td><td align="right" rowspan="1" colspan="1">3.30E+00</td><td align="right" rowspan="1" colspan="1">4.60E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic Myeloid Leukemia Signalling</td><td align="right" rowspan="1" colspan="1">3.20E+00</td><td align="right" rowspan="1" colspan="1">4.30E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiproliferative Role of TOB in T Cell Signalling</td><td align="right" rowspan="1" colspan="1">2.27E+00</td><td align="right" rowspan="1" colspan="1">7.69E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Factors Promoting Cardiogenesis</td><td align="right" rowspan="1" colspan="1">2.16E+00</td><td align="right" rowspan="1" colspan="1">3.26E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic Fibrosis</td><td align="right" rowspan="1" colspan="1">1.99E+00</td><td align="right" rowspan="1" colspan="1">1.99E-02</td></tr></tbody></table></alternatives></table-wrap><fig id="pone.0160517.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.g006</object-id><label>Fig 6</label><caption><title>Diseases and biological functions identified from the sets of DM loci input into IPA for chondrogenic, osteogenic and tenogenic engineered tissues.</title><p>A. Heatmap of the top 20 diseases and biological functions identified using IPA comparison analysis with significant activation z scores (infers the activation state of regulation). Scale relates to activation Z scores were green is a positive activation z-score (activated) and red is a negative score (inhibited). B. A cell differentiation network was identified in all engineered tissue types. The network shown includes DM genes identified in tenogenic tissues. C. The network &#x02018;congenital anomaly of the musculoskeletal system&#x02019; was activated in tenogenic tissues. In networks red genes relates to those hypomethylated and green hypermethylated in tissues derived from older MSCs.</p></caption><graphic xlink:href="pone.0160517.g006"/></fig><p>Next we wanted to determine to what degree the age-related gene expression differences among engineered tissue types are affected by epigenetic changes. The methylation of gene promoters and/or enhancers is known to correlate with decreased gene expression, contrastingly methylation within non-enhancer regions of the gene body correlates with increased gene expression [<xref rid="pone.0160517.ref046" ref-type="bibr">46</xref>]. Therefore for chondrogenic, osteogenic and tenogenic tissues we compared DEGs from RNASeq with location of DMLs and found 10, 13 and 4 genes identified in both data sets for comparison (<xref ref-type="table" rid="pone.0160517.t010">Table 10</xref>).</p><table-wrap id="pone.0160517.t010" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0160517.t010</object-id><label>Table 10</label><caption><title>Summary of genes and DML correlating relationships for chondrogenic, osteogenic and tenogenic engineered tissues.</title></caption><alternatives><graphic id="pone.0160517.t010g" xlink:href="pone.0160517.t010"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Engineered tissue type</th><th align="left" rowspan="1" colspan="1">Gene ID</th><th align="left" rowspan="1" colspan="1">DML (B value)</th><th align="left" rowspan="1" colspan="1">Methylation status in old</th><th align="left" rowspan="1" colspan="1">Log2fold change (RNASeq)</th><th align="left" rowspan="1" colspan="1">Gene expression status in old</th><th align="left" rowspan="1" colspan="1">Location of methylation</th><th align="left" rowspan="1" colspan="1">Promoter/enhancer/body</th><th align="left" rowspan="1" colspan="1">Data correlation</th></tr></thead><tbody><tr><td align="center" rowspan="10" colspan="1">Chondrogenic</td><td align="left" rowspan="1" colspan="1">FAM134B</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-2.6</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body;TSS200;5UTR</td><td align="left" rowspan="1" colspan="1">body, enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">H19</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-6.8</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="char" char="." rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">IRS2</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KYNU</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-8.0</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">LRCH2</td><td align="char" char="." rowspan="1" colspan="1">-0.2</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">-3.2</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-8.1</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body;1stExon;5UTR</td><td align="left" rowspan="1" colspan="1">body, promoter</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">MAPK10</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-2.9</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">5UTR;1stExon</td><td align="left" rowspan="1" colspan="1">promoter</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">MYO7A</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-3.0</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">TSS200;TSS200;TSS200</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">TMEM186</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">3UTR</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="center" rowspan="13" colspan="1">Osteogenic</td><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-7.0</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body;3UTR</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">TNXB</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-6.9</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">WISP2</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-3.1</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">TSS200</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">NTNG1</td><td align="char" char="." rowspan="1" colspan="1">-0.1</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">-2.6</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">TBX18</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-1.8</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">MACROD2</td><td align="char" char="." rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body;TSS1500</td><td align="left" rowspan="1" colspan="1">body, promoter</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">ITIH5</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">KIAA1244</td><td align="char" char="." rowspan="1" colspan="1">-0.4</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB7</td><td align="char" char="." rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body</td><td align="left" rowspan="1" colspan="1">body</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB6</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">TSS1500</td><td align="left" rowspan="1" colspan="1">promoter</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">OCA2</td><td align="char" char="." rowspan="1" colspan="1">-0.6</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">3.8</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body; TS1500</td><td align="left" rowspan="1" colspan="1">body, enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">MKRN3</td><td align="char" char="." rowspan="1" colspan="1">-0.3</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">TSS200; 5UTR</td><td align="left" rowspan="1" colspan="1">promoter</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="center" rowspan="4" colspan="1">Tenogenic</td><td align="left" rowspan="1" colspan="1">HOXA3</td><td align="char" char="." rowspan="1" colspan="1">-0.7</td><td align="left" rowspan="1" colspan="1">hypermethylated</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">5UTR;TSS1500</td><td align="left" rowspan="1" colspan="1">promoter</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB6</td><td align="char" char="." rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">TSS1500</td><td align="left" rowspan="1" colspan="1">promoter</td><td align="left" rowspan="1" colspan="1">yes</td></tr><tr><td align="left" rowspan="1" colspan="1">MAB21L2</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">-6.8</td><td align="left" rowspan="1" colspan="1">lower old</td><td align="left" rowspan="1" colspan="1">Body;5UTR, TSS1500</td><td align="left" rowspan="1" colspan="1">body, enhancer</td><td align="left" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">PITX2</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">hypomethylated</td><td align="char" char="." rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">higher old</td><td align="left" rowspan="1" colspan="1">Body;5UTR, TSS1500</td><td align="left" rowspan="1" colspan="1">body, enhancer</td><td align="left" rowspan="1" colspan="1">yes</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t010fn001"><p>The 3'UTR is encompassed in the gene body. The promoter is classified as the 5'UTR up to 1500bp upstream of the start codon. TSS; transcription start site, enhancer; where probes are within identified enhancer regions.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>Adult MSCs are an appealing source for cell-based treatment for musculoskeletal diseases and injury [<xref rid="pone.0160517.ref047" ref-type="bibr">47</xref>]. Our previous work in bone-marrow-derived MSCs using a systems biology approach demonstrated an altered phenotype in MSC ageing at a number of levels, implicating roles for inflammageing and mitochondrial ageing [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. The changes identified represented novel insights into the ageing process, with implications for stem cell therapies in older patients.</p><p>Tissue engineering aims to develop biomimetic tissues that recapitulate biological, structural and functional characteristics of native tissue. However there is sparse global information available on the effect of donor age on engineered musculoskeletal tissues at the transcriptome and methylome level. Age-related changes have potential implications for the tissue-engineering strategies used for enhancing musculoskeletal repair. Furthermore the study of musculoskeletal ageing in bone, cartilage and tendon are usually undertaken in seclusion and it is frequently difficult to attain aged matched tissue samples in humans. Therefore we propose our approach as a potential model of musculoskeletal ageing that could be probed further to identify factors that may aid in recapitulation of a younger tissue phenotype.</p><p>It is known that the site of MSC extraction can affect cell behaviour [<xref rid="pone.0160517.ref049" ref-type="bibr">49</xref>] we therefore used MSCs derived from alveolar bone. Additionally, as low oxygen tension improves MSC vitality and metabolic state in culture [<xref rid="pone.0160517.ref050" ref-type="bibr">50</xref>] all MSCs and then subsequently tissues were cultured in 5% oxygen tension. Standard methods of engineered tissue characterisation were undertaken following chondrogenic and osteogenic differentiation.</p><p>Transcriptome profiling is a key method for functional characterization of cells and tissues. However one challenge of this study was the integration of the different types of data. We used gene ontology, network analysis and annotated of the pathways identified. However, due to limited information on the donors we were unable to integrate key environmental factors such as nutrition and other lifestyle features which can alter molecular measurements. Other potential limitations of the study include small sample size and significance threshold filtering which can affect the subsequent pathway/network analysis.</p><p>Epigenetic processes have been implicated in age-related musculoskeletal diseases such as osteoarthritis [<xref rid="pone.0160517.ref021" ref-type="bibr">21</xref>] and osteoporosis (reviewed [<xref rid="pone.0160517.ref051" ref-type="bibr">51</xref>]). This study identified a number of epigenetic molecular classes including small non-coding RNAs; small nucleolar RNAs, small cajal body RNA (scaRNAs), miRs and lncRNAs.</p><p>Our study found weak age-related effects on expression at the miR level with no DE small RNAs in chondrogenic engineered tissues. The low mapping in chondrogenic samples implies that RNA populations or fragments other than the targeted small RNA were the input material into the library prep workflows. Further investigation did indeed demonstrate that the low percentage of alignments to the small RNA reference dataset corresponds to a high mapping percentage to rRNA in chondrogenic samples. However the percentage of mapping to rRNA for old and young samples was similar resulting in a lower sequencing depth which may reduce the statistical power in differential expression analysis. This effect was roughly similar for the two sample groups. Therefore, the count values are usable values, though the statistical power may be weaker due to lower sequencing depth. Compared to tenogenic and osteogenic, no DE miRNA detected from chondrogenic tissue is best explained by either no existence of DE miRNA, or existing DE miRNA was not detected due to lack enough statistical power.</p><p>Among the miR expression of which was differentially expressed in the osteogenic tissues from adult and old donors, miRs with known function in bone biology were validated: let-7 [<xref rid="pone.0160517.ref052" ref-type="bibr">52</xref>], miR-21 [<xref rid="pone.0160517.ref053" ref-type="bibr">53</xref>], miR-30 [<xref rid="pone.0160517.ref054" ref-type="bibr">54</xref>], miR-96 [<xref rid="pone.0160517.ref055" ref-type="bibr">55</xref>], miR-27 [<xref rid="pone.0160517.ref056" ref-type="bibr">56</xref>], and miR-140 [<xref rid="pone.0160517.ref057" ref-type="bibr">57</xref>]. Interestingly, among predicted targets of these miRs are genes and proteins regulated in MSC from adult and old donors as shown. For example, MMP16, predicted target of miRs miR-27, miR-30 and miR-140, is an important protein regulating bone homeostasis through regulating osteocyte differentiation [<xref rid="pone.0160517.ref058" ref-type="bibr">58</xref>]. Other genes of interest, predicted to be target of more than one of the validated miRs, include members of the ADAMTS family, key to cartilage and bone homeostasis [<xref rid="pone.0160517.ref059" ref-type="bibr">59</xref>], interleukin 18 with important role in bone metabolism [<xref rid="pone.0160517.ref060" ref-type="bibr">60</xref>]. Several genes with a not yet established function in MSC or bone biology, however reported to be expressed in these cells or tissues have also been characterised as DE in this study and are predicted target genes of miRs here validated, for example desmoglein 2 [<xref rid="pone.0160517.ref061" ref-type="bibr">61</xref>].</p><p>Interestingly, the expression of all miRs in the osteogenic tissues was downregulated in tissues from older donors. This may be due to defective miRNA biogenesis machinery [<xref rid="pone.0160517.ref062" ref-type="bibr">62</xref>] or decreased ability of the MSCs from older donors to undergo the osteogenic differentiation pathway [<xref rid="pone.0160517.ref063" ref-type="bibr">63</xref>]. Interestingly, the lower levels of expression of the enzyme associated with miR production, Dicer, in MSCs have been associated with their decreased differentiation potential [<xref rid="pone.0160517.ref062" ref-type="bibr">62</xref>].</p><p>We have also validated DE of miRs: miR-500 and miR-548j in the tenogenic tissues from young and older donors. It has been shown that miRs may play a role in tendon homeostasis [<xref rid="pone.0160517.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0160517.ref065" ref-type="bibr">65</xref>], however little is still understood about the role of miRs in tenogenic differentiation or tendon homeostasis. Based on target prediction databases), miRs: mir-500 and miR-548j may be regulating processes associated with matrix remodelling which are important in both tendon formation and maintenance, as well as healing. Interestingly, miR-548j is predicted to target peroxisome proliferator-activated receptor gamma (PPARG), a gene differentially expressed in tenogenic tissues from young and older MSCs donors. PPARG has been shown to be involved in tendon healing [<xref rid="pone.0160517.ref066" ref-type="bibr">66</xref>] further indicating the potential involvement of miR-548j in tendon repair.</p><p>To summarise, we have validated DE of miRs and their predicted target genes in the osteogenic and tenogenic tissues from young and older donors that may be associated with the decreased function of MSC from older donors and of relevance to MSC-based therapies.</p><p>LncRNAs play important roles in age-related diseases. Evidence is emerging that lncRNAs affect the molecular processes that underlie age-associated phenotypes. LncRNAs modulate gene expression patterns at the transcriptional, post-transcriptional and post-translational level. They affect many cellular processes relevant to ageing biology such as proliferation, differentiation and senescence (reviewed [<xref rid="pone.0160517.ref067" ref-type="bibr">67</xref>]). We identified a catalogue of lncRNAs for further work to define their roles in musculoskeletal ageing as although studies suggest the majority are functional only a few established biological relevance [<xref rid="pone.0160517.ref068" ref-type="bibr">68</xref>]. In tenogenic tissues we identified XIST as having a reduced expression in older tissues. XIST, responsible for imprinting controls epigenetic changes through DNA methylation and declines in senescence; though its function in this is unknown [<xref rid="pone.0160517.ref069" ref-type="bibr">69</xref>].</p><p>In transcriptomic studies we used gene ontology and network analysis tools to study pathways affected by MSC donor age. However, there are a few interesting findings for the some individual genes. Chondrogenic tissues were the most affected engineered tissue type with age demonstrated by the number of DEGs, whilst tenogenic were the least age-affected engineered tissue. Whilst principally large &#x02018;omics&#x02019; datasets are analysed using network analysis to understand the overall effects of expression changes in the tissue, there were a number of interesting findings at the individual gene level that warrant discussion. In chondrogenic tissues the most DE gene was neurotrophin-3 (NTF3); highly expressed in young. This was not reflected in DML across the gene. NTF3 is an important gene in arthritic processes within the joint [<xref rid="pone.0160517.ref070" ref-type="bibr">70</xref>], produced by inflammatory cells of the nervous system as well as connective tissue [<xref rid="pone.0160517.ref071" ref-type="bibr">71</xref>], with survival-promoting and trophic effects on chondrocytes [<xref rid="pone.0160517.ref072" ref-type="bibr">72</xref>]. There is also a down-regulation of NTF expression in chondrocytes in arthritis [<xref rid="pone.0160517.ref073" ref-type="bibr">73</xref>]. Age-related changes in mouse brain have also been reported [<xref rid="pone.0160517.ref074" ref-type="bibr">74</xref>]. In osteogenic and tenogenic tissues ALX homeobox-1 had the most reduced expression in old similar to ageing MSCs [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. It is important in skeletal development and we previously demonstrated an increased expression in old tendon [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>]. Along with Homeobox (Hox) B7 (lower in old) and Mab-21-like 2 (higher in old) it was DE in all engineered tissue types and ageing MSCs [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. HOX genes have been implicated in ageing of tissues [<xref rid="pone.0160517.ref075" ref-type="bibr">75</xref>] including tendon [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>]. Furthermore HOX genes are required for tissue appropriate regeneration [<xref rid="pone.0160517.ref076" ref-type="bibr">76</xref>] and may be involved in the timing of ageing [<xref rid="pone.0160517.ref049" ref-type="bibr">49</xref>]. HOX-mediated transcriptional memory may reduce stem cell-mediated tissue regeneration [<xref rid="pone.0160517.ref077" ref-type="bibr">77</xref>]. Therefore this has special relevance to tissue engineering and musculoskeletal repair in ageing marking them as an interesting gene for further work in tissue engineering using MSCs.</p><p>Pathway analysis identified similar age-related changes at the molecular and cellular function level from input DE genes for the functions &#x02018;cell death and survival&#x02019;, &#x02018;cell morphology&#x02019;, and &#x02018;cell growth and proliferation&#x02019;. This suggests that although the DEG may be different between engineered tissue types the age-related pathways involved at this level are similar. Interestingly in ageing MSCs we demonstrated age-related changes in gene profiles included differences in cell proliferation, signalling, function and maintenance suggesting an age-related loss in MSCs ability to respond to biological cues [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. Thus these changes seem to have impacted on all classes of engineered tissues.</p><p>The top canonical pathways in chondrogenic and tenogenic tissues were related to oxidative stress similar to that previously identified in tenocytes exposed to extracellular glucose [<xref rid="pone.0160517.ref078" ref-type="bibr">78</xref>] and ageing chondrocytes [<xref rid="pone.0160517.ref079" ref-type="bibr">79</xref>]. Mitochondrial dysfunction and oxidative phosphorylation were the most significant in chondrogenic tissues similar to ageing MSCs [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. One hallmark of ageing is mitochondrial dysfunction and alterations in redox balance could account for the observed reduction in cellular function associated with age [<xref rid="pone.0160517.ref080" ref-type="bibr">80</xref>]. The mitochondria represent an important source of cellular ROS and recent evidence suggests that age-related oxidative stress can disrupt normal physiological cell signalling pathways. Human chondrocytes isolated from older adult chondrocytes exhibited increased peroxiredoxin (PRX) hyperoxidation, particularly for mitochondrial PRXs, when compared to younger chondrocytes in a recent study. PRXs represent a key antioxidant system, and oxidative stress mediated hyperoxidation leads to inhibition of PRX function, and a reduction in antioxidant capacity. PRX hyperoxidation was associated with inhibition of downstream pro-survival signalling and up-regulation of pro-death signalling which led to chondrocyte cell death [<xref rid="pone.0160517.ref079" ref-type="bibr">79</xref>]. Additionally, oxidative stress mediated inhibition of pro-survival cell signalling has also been demonstrated in another recent study supporting the theory that high levels of oxidative stress, such that are observed in ageing tissues, could lead to oxidative stress mediated alterations in cell signalling and contribute to the ageing phenotype and the development of age-related disease such as osteoarthritis [<xref rid="pone.0160517.ref081" ref-type="bibr">81</xref>]. The current study also identified significant alterations in cell signalling pathways in chondrogenic tissues. Thus the use of older MSC donors for cartilage tissue engineering could result in increased oxidative stress within the engineered tissue which could alter normal physiological signal transduction which could have significant consequences for the synthesis and degradation of cartilage matrix components [<xref rid="pone.0160517.ref082" ref-type="bibr">82</xref>]. Peroxisome proliferator-activated receptor signalling (PPAR) are key regulators in various age-related processes related to oxidative stress and energy metabolism. PPAR signalling was the dominant pathway in tenogenic tissues. As PPAR signalling has roles in cell proliferation, differentiation and tissue remodelling [<xref rid="pone.0160517.ref083" ref-type="bibr">83</xref>], and these pathways were also identified through a network of DE genes, this could have detrimental effects on engineered tendon from older MSCs. Furthermore PPAR signalling affects the impairment in mitochondrial biogenesis demonstrated in OA chondrocytes [<xref rid="pone.0160517.ref084" ref-type="bibr">84</xref>].</p><p>For osteogenic tissues age-related changes in genes involved in VDR/RXR (vitamin D receptor (VDR)-9-cis-retinoic acid receptor (RXR)) were identified. The classical actions of vitamin D3 are through this signalling pathway facilitating transcription of genes important in bone for the expression of several proteins including osteopontin [<xref rid="pone.0160517.ref085" ref-type="bibr">85</xref>] and in osteoblasts transcription of nuclear factor-kappaB ligand (RANK-L); important for the activation and differentiation of the osteoclasts [<xref rid="pone.0160517.ref086" ref-type="bibr">86</xref>]. A change in VDR expression with ageing has been reported in rat bone [<xref rid="pone.0160517.ref087" ref-type="bibr">87</xref>] and a reduction in ageing mice osteoblasts [<xref rid="pone.0160517.ref088" ref-type="bibr">88</xref>]. A significant effect on cell differentiation and survival is evident following a reduction in VDR activity in bone. Furthermore a decrease in VDR may be partially responsible for increased levels of apoptosis in ageing osteoblasts [<xref rid="pone.0160517.ref088" ref-type="bibr">88</xref>], together with reduction in bone mineralization proteins; osteopontin and osteocalcin [<xref rid="pone.0160517.ref089" ref-type="bibr">89</xref>]. In osteogenesis from ageing MSCs there are alterations in osteocalcin expression with negative effects on proliferation and differentiation capacity of BMSCs in culture [<xref rid="pone.0160517.ref006" ref-type="bibr">6</xref>]. Another study demonstrated osteogenic potential of ageing MSCs was reduced as measured by Alizarin Red staining (which stains calcium deposits) [<xref rid="pone.0160517.ref090" ref-type="bibr">90</xref>]. Together these findings suggest that the reduced osteogenic potential of ageing MSCs could in part be due to a dysregulation of VDR/RXR signalling. The most significant canonical pathways related to changes in the methylation patterns for osteogenic tissues was active AMP-activated protein kinase (AMPK) signalling. AMPK is highly affected by age and may be a crucial cell signalling pathway that regulates cell function. Age related decline in AMPK plays a key role in the observed loss of function, disordered bioenergetics and metabolism observed in ageing cells and likely contributes to age related disease [<xref rid="pone.0160517.ref091" ref-type="bibr">91</xref>]. Indeed OA chondrocytes are deficient in the metabolic biosensors active AMPK [<xref rid="pone.0160517.ref084" ref-type="bibr">84</xref>].</p><p>In our previous cartilage ageing equine transcriptomics study [<xref rid="pone.0160517.ref022" ref-type="bibr">22</xref>] we identified an over representation of DEGs (principally reduced in ageing) involved in pathways for extracellular matrix, degradative proteases and matrix synthetic enzymes and cytokines/growth factors and Wnt signalling. In our aged tissue engineered cartilage DEGs principle pathways involved mitochondrial dysfunction and oxidative phosphorylation. In both ageing cartilage and ageing tissue engineered cartilage the pathway hepatic fibrosis was identified with the genes COL2, COL9 and COL24 DE in both data sets. However for cartilage this was evident as reduced expression in ageing whereas in tissue-engineered cartilage they were increase in ageing. Thus the age-related changes in cartilage are not reflected using tissue-engineered cartilage. Our Achilles tendon ageing RNASeq study [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>] determined the top networks for DEGs were from cellular function, cellular growth, and cellular cycling pathways. In tissue-engineered tendon the main pathways from DEGs were signalling pathways with large proportion of DEGs being transcription factors. There were no overlaps in the pathways with ageing between tendon and tissue-engineered tendon. It seems that from these results that age-related changes in cartilage and tendon are not reflected at the transcriptome level to those in MSC-derived tissue engineered cartilage and tendon. This could be due to the method/conditions of tissue generation, a more embryonic phenotype in engineered tissues [<xref rid="pone.0160517.ref092" ref-type="bibr">92</xref>](which may be altered with the addition of loading or growth factors [<xref rid="pone.0160517.ref093" ref-type="bibr">93</xref>]) or disparate ageing mechanism&#x02019;s. Thus whilst tissue-engineering may provide too artificial a systems to study age-related changes in MSC biology per-se, our findings are important in relation to therapeutic cell source decisions.</p><p>In tissues derived from ageing MSCs we identified changes in expression level and differences in the relative balance of splice products. AS; the production of multiple mRNA isoforms from a single gene due to alternative choice of exons or splice sites during pre-mRNA splicing is a major source of protein diversity for higher organisms, and is frequently regulated in a tissue-specific manner. It is estimated that up to 90 percent of human genes have multiple isoforms [<xref rid="pone.0160517.ref094" ref-type="bibr">94</xref>]. Splice variants from the same gene can produce proteins with discrete properties and diverse (including antagonistic) functions. Furthermore, a number of genetic mutations involved in human disease have been mapped to changes in splicing signals or sequences that regulate splicing. Thus, an understanding of changes in splicing patterns is critical to a comprehensive understanding of biological regulation and disease mechanisms. There is a growing interest in the role of AS in normal tissues [<xref rid="pone.0160517.ref095" ref-type="bibr">95</xref>], development [<xref rid="pone.0160517.ref096" ref-type="bibr">96</xref>] and disease (reviewed [<xref rid="pone.0160517.ref097" ref-type="bibr">97</xref>]), but little is known on its role in MSC ageing and tissue engineering. Changes in AS may have a major impact on cell survival [<xref rid="pone.0160517.ref098" ref-type="bibr">98</xref>] and post-translational modifications [<xref rid="pone.0160517.ref099" ref-type="bibr">99</xref>].</p><p>Our study demonstrated that donor MSC age has an effect on splicing events in all engineered tissue types, similar to an ageing study in peripheral blood leukocytes [<xref rid="pone.0160517.ref100" ref-type="bibr">100</xref>], suggesting that modification of mRNA processing may be a feature of human ageing. GO ontology demonstrated enrichment in genes associated principally with metabolic processes in genes undergoing AS in all engineered tissue types. AS in metabolic processes is a frequent phenomenon in diseases such as cancer [<xref rid="pone.0160517.ref101" ref-type="bibr">101</xref>] but also in ageing brain [<xref rid="pone.0160517.ref102" ref-type="bibr">102</xref>] and MSCs [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>]. Further analysis of the tenogenic AS genes identified carbohydrate and lipid metabolism as significant metabolic pathways affected in ageing. In tenogenic tissuesthe principal network identified in IPA was cell signalling, interaction function and maintenance. This suggests that similar to some cancer cells [<xref rid="pone.0160517.ref098" ref-type="bibr">98</xref>] in tendon tissues derived from ageing MSCs there may be expression of isoforms that alter cell survival. We have previously observed an age-associated disruption to the balance of alternatively expressed isoforms for selected genes in tendon ageing [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>]. In AS affected genes for chondrogenic tissues with age were related to cell death and survival, and growth and proliferation of connective tissue. Interestingly a recent study found pyruvate dehydrogenase kinase isoform 2-mediated alternative splicing switches hypoxia-inducible death protein from cell death to cell survival in cancer cells [<xref rid="pone.0160517.ref103" ref-type="bibr">103</xref>].</p><p>Though there was little overlap between DEG and DML those that were displayed a good correlation of DNA methylation with differentially expressed genes (promoter increased methylation; reduced gene expression, gene body increased methylation; increased gene expression). There are a number of possibilities as to why correlation between gene expression and DML was poor. DNA methylation is stable so the methylation changes evident may be associated with ancestral gene expression differences. For instance in the study we differentiated MSCs for 21&#x02013;28 days. There may have been a gene expression changes between day 0 and 7 accompanied by a methylation change. The gene expression could then return back to basal day 0 levels at day 28 when gene expression was measured, but the methylation change remains. Thus a DNA methylation change may not be accompanied by gene expression change as although gene expression did alter, it is not different at the time points measured. Another possibility is that gene enhancers can be located within the gene body of a different gene. Thus a DML within the gene body of gene A may actually be within the enhancer of gene B and so the DML may be associated with a change in gene B but not gene A in which we assessed the effect of the DML on gene A. Finally gene body methylation can be associated with alternative splicing and transcription from alternative/cryptic transcription start site. These may not be have been detected in our RNASeq analysis.</p><p>DNA methylation provides a stable and heritable gene regulatory mechanism enabling cells to alter the expression of many genes. Alterations in DML have previously been seen in ageing tissues [<xref rid="pone.0160517.ref104" ref-type="bibr">104</xref>] as a global hypomethylation, as well as aged MSCs [<xref rid="pone.0160517.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0160517.ref049" ref-type="bibr">49</xref>]. Significant age-related DMLs, both tissue specific and common were identified in all tissue types. DNA methylation also has a role in genomic imprinting (the epigenetic occurrence by which certain genes are expressed in a parent-of-origin-given manner) by regulating the differential expression of maternal and paternal imprinted genes. It is also important in DNA damage/repair and genomic instability [<xref rid="pone.0160517.ref105" ref-type="bibr">105</xref>]. Furthermore a number of disease have been associated with aberrant DNA methylation (reviewed [<xref rid="pone.0160517.ref106" ref-type="bibr">106</xref>]). Thus alterations in methylation in engineered tissues may have further consequences than gene expression changes alone. For instance altered methylation may affect the DNA damage response resulting in senescence and apoptosis [<xref rid="pone.0160517.ref107" ref-type="bibr">107</xref>]. Further work is required to decipher the impact of the DNA methylation changes evident in this study on DNA damage and genomic instability in musculoskeletal engineered tissues with ageing.</p><p>Methylation has dual and opposing roles in the gene expression regulation. In promoter regions DNA methylation is correlated with transcriptional repression, while in gene bodies it is generally associated with high expression levels [<xref rid="pone.0160517.ref049" ref-type="bibr">49</xref>]. This paradox emphasizes the diverse involvement of methylation in specific genomic and cellular contexts. We described common age-related pathways from DML of skeletal system morphogenesis, regulation of transcription regulation (both principally due to DML in HOX genes) and cell proliferation (also identified in RNASeq data).</p><p>The network &#x02018;skeletal and muscular development and function&#x02019; significant in all tissues due to DMLs was principally due to the enrichment of homeotic or HOX genes, similar to studies in ageing MSCs [<xref rid="pone.0160517.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0160517.ref049" ref-type="bibr">49</xref>]. HOX gene expression is tightly regulated temporally during vertebrate development. An association between HOX genes and longevity has been previously proposed [<xref rid="pone.0160517.ref108" ref-type="bibr">108</xref>]. HOXB7 (chondrogenic), HOXB6 and HOXB7 (osteogenic) and HOXA3 and HOXB6 (tenogenic) were also DEGs in the RNASeq study. However, for HOXB7 (osteogenic) and HOXA3 (tenogenic) DEG did not correlate with DML position. Despite this, the dysregulation of HOX genes at the mRNA and epigenetic level consolidate their role in both MSC ageing and in engineered tissues from ageing MSCs.</p><p>An interesting signature of age-related DML was that between 40% (chondrogenic and osteogenic) and 50% (tenogenic) of the top 20 most DML for each engineered tissue type were transcription factors. DML not only transcriptionally regulates gene expression but in ageing we identified significant regulation of the transcription factors. In our study of ageing tendon we identified an overrepresentation of DE transcription factors in ageing tendon [<xref rid="pone.0160517.ref023" ref-type="bibr">23</xref>] suggesting they may have a pivotal role in tendon ageing and tissue engineered tendon. Conversely in our cartilage ageing study there were few age-related DE transcription factors. Furthermore many age-related DML identified in all engineered tissue types resulted in &#x02018;differentiation of cells&#x02019; being highlighted. Site specific CpG site methylation changes can affect MSC chondrogenic differentiation [<xref rid="pone.0160517.ref109" ref-type="bibr">109</xref>] whilst alterations in MSC potential have been previously noted [<xref rid="pone.0160517.ref110" ref-type="bibr">110</xref>]. However &#x02018;cell survival&#x02019; networks relating to DML were affected in chondrogenic and osteogenic tissues only suggesting distinct age-related methylation patterns between tissue types with potential distinct consequences to engineered tissues.</p><p>There was an age-related activation in the function differentiation in all tissues due to DMLs. The DM at some of these loci could be responsible for changes in differentiation potential previously described in chondrogenesis and osteogenesis from ageing MSCs. Studies have described a more rapid decline in differentiation potential for osteoblastic and chondrogenic lineages relative to adipogenic differentiation [<xref rid="pone.0160517.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0160517.ref111" ref-type="bibr">111</xref>]. No studies have investigated tenogenic differentiation potential with age. Our results would suggest based on the amount of gene expression changes, AS and DML alterations that tenogenic differentiation is likely to be more maintained with ageing compared to chondrogenic and osteogenic lineages. However this hypothesis needs validation. Additional parameters such as histone modification would benefit the analysis but this was beyond the financial scope of the study. Dynamic histone methylation can contribute to the ageing process through influencing DNA repair and transcriptional regulation of ageing processes (reviewed [<xref rid="pone.0160517.ref112" ref-type="bibr">112</xref>]).</p></sec><sec sec-type="conclusions" id="sec019"><title>Conclusion</title><p>Context-dependent DNA methylation plays a critical role in regulating gene transcription, thereby serving as an important epigenetic marker or regulator in many biological activities. Taken together our RNASeq and DNA methylation results in engineered tissues suggest an age-related loss in the differentiated cells ability to respond to biological cues. Age-related cellular dysfunctions have been hypothesized to results in musculoskeletal age-related diseases such as OA, osteoporosis and tendinopathy. These results have significant implications for therapeutic cell source decisions (autologous or allogeneic) revealing the necessity of approaches to improve functionality of ageing MSCs.</p></sec><sec sec-type="supplementary-material" id="sec020"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0160517.s001"><label>S1 File</label><caption><title>Table of primer sequences.</title><p>(DOCX)</p></caption><media xlink:href="pone.0160517.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s002"><label>S2 File</label><caption><title>Supplementary methods.</title><p>(DOCX)</p></caption><media xlink:href="pone.0160517.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s003"><label>S3 File</label><caption><title>RNASeq reads summary table.</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s004"><label>S4 File</label><caption><title>SmallRNASeq reads summary table.</title><p>(XLS)</p></caption><media xlink:href="pone.0160517.s004.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s005"><label>S5 File</label><caption><title>Table of top 10 expressed snoRNAs and microRNAs using FPKM.</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s006"><label>S6 File</label><caption><title>Age-related differentially expressed genes fromtissues (&#x000b1;1.4 log2 fold change, FDR&#x0003c;0.05) for each tissues type.</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s007"><label>S7 File</label><caption><title>RNASeq data including FPKM.</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s007.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s008"><label>S8 File</label><caption><title>MA plots RNASeq and smallSeq.</title><p>(DOCX)</p></caption><media xlink:href="pone.0160517.s008.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s009"><label>S9 File</label><caption><title>Tables for each tissue type containing genes in which there was a significant difference in splicing events.</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s009.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s010"><label>S10 File</label><caption><title>MicroRNA-mRNA expression pairing using differentially expressed miRs and mRNA.</title><p>(DOCX)</p></caption><media xlink:href="pone.0160517.s010.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s011"><label>S11 File</label><caption><title>Tables for each engineered tissue type of differentially methylated loci (with FDR&#x0003c;0.05 and 10% mean methylation difference).</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s011.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0160517.s012"><label>S12 File</label><caption><title>Tables for each tissue type of DM at the site, promoter, CgG isalnd and gene level (FDR adjusted p-value &#x0003c;0.05 and methylation difference of 15% for promter CpG island and genes and FDR adjusted p-value &#x0003c;0.01 and methylation difference of 15% at site level).</title><p>(XLSX)</p></caption><media xlink:href="pone.0160517.s012.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Luke Tregilgas for transcript stabilisation analysis, Sophie Sutton for assistance with the gene expression validation and analysis and Aaron Dale and Louise Reynard for critical evaluation of the manuscript. We also thank Danae Zamboulis for her assistance with image production.</p></ack><ref-list><title>References</title><ref id="pone.0160517.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Orth</surname><given-names>P</given-names></name>, <name><surname>Rey-Rico</surname><given-names>A</given-names></name>, <name><surname>Venkatesan</surname><given-names>JK</given-names></name>, <name><surname>Madry</surname><given-names>H</given-names></name>, <name><surname>Cucchiarini</surname><given-names>M</given-names></name>. <article-title>Current perspectives in stem cell research for knee cartilage repair</article-title>. <source>Stem cells and cloning: advances and applications</source>. <year>2014</year>;<volume>7</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/SCCAA.S42880">10.2147/SCCAA.S42880</ext-link></comment> ; PubMed Central PMCID: PMC3897321.<?supplied-pmid 24520197?><pub-id pub-id-type="pmid">24520197</pub-id></mixed-citation></ref><ref id="pone.0160517.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Gomez-Barrena</surname><given-names>E</given-names></name>, <name><surname>Rosset</surname><given-names>P</given-names></name>, <name><surname>Lozano</surname><given-names>D</given-names></name>, <name><surname>Stanovici</surname><given-names>J</given-names></name>, <name><surname>Ermthaller</surname><given-names>C</given-names></name>, <name><surname>Gerbhard</surname><given-names>F</given-names></name>. <article-title>Bone fracture healing: cell therapy in delayed unions and nonunions</article-title>. <source>Bone</source>. <year>2015</year>;<volume>70</volume>:<fpage>93</fpage>&#x02013;<lpage>101</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bone.2014.07.033">10.1016/j.bone.2014.07.033</ext-link></comment> .<?supplied-pmid 25093266?><pub-id pub-id-type="pmid">25093266</pub-id></mixed-citation></ref><ref id="pone.0160517.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Docheva</surname><given-names>D</given-names></name>, <name><surname>Muller</surname><given-names>SA</given-names></name>, <name><surname>Majewski</surname><given-names>M</given-names></name>, <name><surname>Evans</surname><given-names>CH</given-names></name>. <article-title>Biologics for tendon repair</article-title>. <source>Advanced drug delivery reviews</source>. <year>2015</year>;<volume>84</volume>:<fpage>222</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.addr.2014.11.015">10.1016/j.addr.2014.11.015</ext-link></comment> ; PubMed Central PMCID: PMC4519231.<?supplied-pmid 25446135?><pub-id pub-id-type="pmid">25446135</pub-id></mixed-citation></ref><ref id="pone.0160517.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Oh</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>YD</given-names></name>, <name><surname>Wagers</surname><given-names>AJ</given-names></name>. <article-title>Stem cell aging: mechanisms, regulators and therapeutic opportunities</article-title>. <source>Nature medicine</source>. <year>2014</year>;<volume>20</volume>(<issue>8</issue>):<fpage>870</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.3651">10.1038/nm.3651</ext-link></comment> ; PubMed Central PMCID: PMC4160113.<?supplied-pmid 25100532?><pub-id pub-id-type="pmid">25100532</pub-id></mixed-citation></ref><ref id="pone.0160517.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Scharstuhl</surname><given-names>A</given-names></name>, <name><surname>Schewe</surname><given-names>B</given-names></name>, <name><surname>Benz</surname><given-names>K</given-names></name>, <name><surname>Gaissmaier</surname><given-names>C</given-names></name>, <name><surname>Buhring</surname><given-names>HJ</given-names></name>, <name><surname>Stoop</surname><given-names>R</given-names></name>. <article-title>Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology</article-title>. <source>Stem Cells</source>. <year>2007</year>;<volume>25</volume>(<issue>12</issue>):<fpage>3244</fpage>&#x02013;<lpage>51</lpage>. Epub 2007/09/18. 2007&#x02013;0300 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1634/stemcells.2007-0300">10.1634/stemcells.2007-0300</ext-link></comment> .<?supplied-pmid 17872501?><pub-id pub-id-type="pmid">17872501</pub-id></mixed-citation></ref><ref id="pone.0160517.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Wei</surname><given-names>G</given-names></name>, <name><surname>Gu</surname><given-names>Q</given-names></name>, <name><surname>Wen</surname><given-names>G</given-names></name>, <name><surname>Qi</surname><given-names>B</given-names></name>, <name><surname>Xu</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Donor Age and Cell Passage Affect Osteogenic Ability of Rat Bone Marrow Mesenchymal Stem Cells</article-title>. <source>Cell Biochem Biophys</source>. <year>2015</year> Epub 2015/01/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12013-014-0500-9">10.1007/s12013-014-0500-9</ext-link></comment> .<?supplied-pmid 25634304?><pub-id pub-id-type="pmid">25634304</pub-id></mixed-citation></ref><ref id="pone.0160517.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Zaim</surname><given-names>M</given-names></name>, <name><surname>Karaman</surname><given-names>S</given-names></name>, <name><surname>Cetin</surname><given-names>G</given-names></name>, <name><surname>Isik</surname><given-names>S</given-names></name>. <article-title>Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells</article-title>. <source>Ann Hematol</source>. <year>2012</year>;<volume>91</volume>(<issue>8</issue>):<fpage>1175</fpage>&#x02013;<lpage>86</lpage>. Epub 2012/03/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00277-012-1438-x">10.1007/s00277-012-1438-x</ext-link></comment> .<?supplied-pmid 22395436?><pub-id pub-id-type="pmid">22395436</pub-id></mixed-citation></ref><ref id="pone.0160517.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Stolzing</surname><given-names>A</given-names></name>, <name><surname>Jones</surname><given-names>E</given-names></name>, <name><surname>McGonagle</surname><given-names>D</given-names></name>, <name><surname>Scutt</surname><given-names>A</given-names></name>. <article-title>Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies</article-title>. <source>Mech Ageing Dev</source>. <year>2008</year>;<volume>129</volume>(<issue>3</issue>):<fpage>163</fpage>&#x02013;<lpage>73</lpage>. Epub 2008/02/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mad.2007.12.002">10.1016/j.mad.2007.12.002</ext-link></comment> S0047-6374(07)00179-0 [pii]. .<?supplied-pmid 18241911?><pub-id pub-id-type="pmid">18241911</pub-id></mixed-citation></ref><ref id="pone.0160517.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Dexheimer</surname><given-names>V</given-names></name>, <name><surname>Mueller</surname><given-names>S</given-names></name>, <name><surname>Braatz</surname><given-names>F</given-names></name>, <name><surname>Richter</surname><given-names>W</given-names></name>. <article-title>Reduced reactivation from dormancy but maintained lineage choice of human mesenchymal stem cells with donor age</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>8</issue>):<fpage>e22980</fpage> Epub 2011/08/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0022980">10.1371/journal.pone.0022980</ext-link></comment> PONE-D-11-04667 [pii]. ; PubMed Central PMCID: PMC3151268.<?supplied-pmid 21850247?><pub-id pub-id-type="pmid">21850247</pub-id></mixed-citation></ref><ref id="pone.0160517.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Payne</surname><given-names>KA</given-names></name>, <name><surname>Didiano</surname><given-names>DM</given-names></name>, <name><surname>Chu</surname><given-names>CR</given-names></name>. <article-title>Donor sex and age influence the chondrogenic potential of human femoral bone marrow stem cells</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>705</fpage>&#x02013;<lpage>13</lpage>. Epub 2010/02/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.joca.2010.01.011">10.1016/j.joca.2010.01.011</ext-link></comment> S1063-4584(10)00041-5 [pii]. ; PubMed Central PMCID: PMC2862807.<?supplied-pmid 20171308?><pub-id pub-id-type="pmid">20171308</pub-id></mixed-citation></ref><ref id="pone.0160517.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Brady</surname><given-names>K</given-names></name>, <name><surname>Dickinson</surname><given-names>SC</given-names></name>, <name><surname>Guillot</surname><given-names>PV</given-names></name>, <name><surname>Polak</surname><given-names>J</given-names></name>, <name><surname>Blom</surname><given-names>AW</given-names></name>, <name><surname>Kafienah</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Human fetal and adult bone marrow-derived mesenchymal stem cells use different signaling pathways for the initiation of chondrogenesis</article-title>. <source>Stem Cells Dev</source>. <year>2014</year>;<volume>23</volume>(<issue>5</issue>):<fpage>541</fpage>&#x02013;<lpage>54</lpage>. Epub 2013/11/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/scd.2013.0301">10.1089/scd.2013.0301</ext-link></comment> ; PubMed Central PMCID: PMC3929258.<?supplied-pmid 24172175?><pub-id pub-id-type="pmid">24172175</pub-id></mixed-citation></ref><ref id="pone.0160517.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Bergman</surname><given-names>RJ</given-names></name>, <name><surname>Gazit</surname><given-names>D</given-names></name>, <name><surname>Kahn</surname><given-names>AJ</given-names></name>, <name><surname>Gruber</surname><given-names>H</given-names></name>, <name><surname>McDougall</surname><given-names>S</given-names></name>, <name><surname>Hahn</surname><given-names>TJ</given-names></name>. <article-title>Age-related changes in osteogenic stem cells in mice</article-title>. <source>J Bone Miner Res</source>. <year>1996</year>;<volume>11</volume>(<issue>5</issue>):<fpage>568</fpage>&#x02013;<lpage>77</lpage>. Epub 1996/05/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jbmr.5650110504">10.1002/jbmr.5650110504</ext-link></comment> .<?supplied-pmid 9157771?><pub-id pub-id-type="pmid">9157771</pub-id></mixed-citation></ref><ref id="pone.0160517.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Fickert</surname><given-names>S</given-names></name>, <name><surname>Schroter-Bobsin</surname><given-names>U</given-names></name>, <name><surname>Gross</surname><given-names>AF</given-names></name>, <name><surname>Hempel</surname><given-names>U</given-names></name>, <name><surname>Wojciechowski</surname><given-names>C</given-names></name>, <name><surname>Rentsch</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Human mesenchymal stem cell proliferation and osteogenic differentiation during long-term ex vivo cultivation is not age dependent</article-title>. <source>J Bone Miner Metab</source>. <year>2011</year>;<volume>29</volume>(<issue>2</issue>):<fpage>224</fpage>&#x02013;<lpage>35</lpage>. Epub 2010/09/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00774-010-0215-y">10.1007/s00774-010-0215-y</ext-link></comment> .<?supplied-pmid 20811759?><pub-id pub-id-type="pmid">20811759</pub-id></mixed-citation></ref><ref id="pone.0160517.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Stenderup</surname><given-names>K</given-names></name>, <name><surname>Justesen</surname><given-names>J</given-names></name>, <name><surname>Clausen</surname><given-names>C</given-names></name>, <name><surname>Kassem</surname><given-names>M</given-names></name>. <article-title>Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells</article-title>. <source>Bone</source>. <year>2003</year>;<volume>33</volume>(<issue>6</issue>):<fpage>919</fpage>&#x02013;<lpage>26</lpage>. Epub 2003/12/18. S8756328203002679 [pii]. .<?supplied-pmid 14678851?><pub-id pub-id-type="pmid">14678851</pub-id></mixed-citation></ref><ref id="pone.0160517.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Leskela</surname><given-names>HV</given-names></name>, <name><surname>Risteli</surname><given-names>J</given-names></name>, <name><surname>Niskanen</surname><given-names>S</given-names></name>, <name><surname>Koivunen</surname><given-names>J</given-names></name>, <name><surname>Ivaska</surname><given-names>KK</given-names></name>, <name><surname>Lehenkari</surname><given-names>P</given-names></name>. <article-title>Osteoblast recruitment from stem cells does not decrease by age at late adulthood</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2003</year>;<volume>311</volume>(<issue>4</issue>):<fpage>1008</fpage>&#x02013;<lpage>13</lpage>. Epub 2003/11/19. S0006291X0302179X [pii]. .<?supplied-pmid 14623282?><pub-id pub-id-type="pmid">14623282</pub-id></mixed-citation></ref><ref id="pone.0160517.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Alt</surname><given-names>EU</given-names></name>, <name><surname>Senst</surname><given-names>C</given-names></name>, <name><surname>Murthy</surname><given-names>SN</given-names></name>, <name><surname>Slakey</surname><given-names>DP</given-names></name>, <name><surname>Dupin</surname><given-names>CL</given-names></name>, <name><surname>Chaffin</surname><given-names>AE</given-names></name>, <etal>et al</etal>
<article-title>Aging alters tissue resident mesenchymal stem cell properties</article-title>. <source>Stem Cell Res</source>. <year>2012</year>;<volume>8</volume>(<issue>2</issue>):<fpage>215</fpage>&#x02013;<lpage>25</lpage>. Epub 2012/01/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.scr.2011.11.002">10.1016/j.scr.2011.11.002</ext-link></comment> S1873-5061(11)00156-5 [pii]. .<?supplied-pmid 22265741?><pub-id pub-id-type="pmid">22265741</pub-id></mixed-citation></ref><ref id="pone.0160517.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kohler</surname><given-names>J</given-names></name>, <name><surname>Popov</surname><given-names>C</given-names></name>, <name><surname>Klotz</surname><given-names>B</given-names></name>, <name><surname>Alberton</surname><given-names>P</given-names></name>, <name><surname>Prall</surname><given-names>WC</given-names></name>, <name><surname>Haasters</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Uncovering the cellular and molecular changes in tendon stem/progenitor cells attributed to tendon aging and degeneration</article-title>. <source>Aging Cell</source>. <year>2013</year>;<volume>12</volume>(<issue>6</issue>):<fpage>988</fpage>&#x02013;<lpage>99</lpage>. Epub 2013/07/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/acel.12124">10.1111/acel.12124</ext-link></comment> ; PubMed Central PMCID: PMC4225469.<?supplied-pmid 23826660?><pub-id pub-id-type="pmid">23826660</pub-id></mixed-citation></ref><ref id="pone.0160517.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>GD</given-names></name>, <name><surname>Liu</surname><given-names>JP</given-names></name>, <name><surname>Wang</surname><given-names>HS</given-names></name>, <name><surname>Liu</surname><given-names>XM</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>miR-135a modulates tendon stem/progenitor cell senescence via suppressing ROCK1</article-title>. <source>Bone</source>. <year>2015</year>;<volume>71</volume>:<fpage>210</fpage>&#x02013;<lpage>6</lpage>. Epub 2014/12/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bone.2014.11.001">10.1016/j.bone.2014.11.001</ext-link></comment> S8756-3282(14)00400-1 [pii]. .<?supplied-pmid 25460182?><pub-id pub-id-type="pmid">25460182</pub-id></mixed-citation></ref><ref id="pone.0160517.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Blakeley</surname><given-names>P</given-names></name>, <name><surname>Fogarty</surname><given-names>NM</given-names></name>, <name><surname>Del Valle</surname><given-names>I</given-names></name>, <name><surname>Wamaitha</surname><given-names>SE</given-names></name>, <name><surname>Hu</surname><given-names>TX</given-names></name>, <name><surname>Elder</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Defining the three cell lineages of the human blastocyst by single-cell RNA-seq</article-title>. <source>Development</source>. <year>2015</year>;<volume>142</volume>(<issue>20</issue>):<fpage>3613</fpage> Epub 2015/10/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/dev.131235">10.1242/dev.131235</ext-link></comment> 142/20/3613 [pii]. ; PubMed Central PMCID: PMC4631772.<?supplied-pmid 26487783?><pub-id pub-id-type="pmid">26487783</pub-id></mixed-citation></ref><ref id="pone.0160517.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Giorda</surname><given-names>K</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Frey</surname><given-names>E</given-names></name>, <name><surname>Taylor</surname><given-names>M</given-names></name>, <name><surname>Barron</surname><given-names>T</given-names></name>, <name><surname>Piper</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>RNA-seq to identify novel markers for neural tissue differentiation</article-title>. <source>The Journal of the Federation of American Societies for Experimental Biology</source>. <year>2014</year>;<volume>28</volume>(<issue>1 (Supplement)</issue>):<fpage>LB211</fpage>.</mixed-citation></ref><ref id="pone.0160517.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Rushton</surname><given-names>MD</given-names></name>, <name><surname>Reynard</surname><given-names>LN</given-names></name>, <name><surname>Barter</surname><given-names>MJ</given-names></name>, <name><surname>Refaie</surname><given-names>R</given-names></name>, <name><surname>Rankin</surname><given-names>KS</given-names></name>, <name><surname>Young</surname><given-names>DA</given-names></name>, <etal>et al</etal>
<article-title>Characterization of the cartilage DNA methylome in knee and hip osteoarthritis</article-title>. <source>Arthritis Rheumatol</source>. <year>2014</year>;<volume>66</volume>(<issue>9</issue>):<fpage>2450</fpage>&#x02013;<lpage>60</lpage>. Epub 2014/05/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.38713">10.1002/art.38713</ext-link></comment> ; PubMed Central PMCID: PMC4314681.<?supplied-pmid 24838673?><pub-id pub-id-type="pmid">24838673</pub-id></mixed-citation></ref><ref id="pone.0160517.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Peffers</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Clegg</surname><given-names>P</given-names></name>. <article-title>Transcriptomic signatures in cartilage ageing</article-title>. <source>Arthritis research &#x00026; therapy</source>. <year>2013</year>;<volume>15</volume>(<issue>4</issue>):<fpage>R98</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/ar4278">10.1186/ar4278</ext-link></comment> ; PubMed Central PMCID: PMC3978620.<?supplied-pmid 23971731?><pub-id pub-id-type="pmid">23971731</pub-id></mixed-citation></ref><ref id="pone.0160517.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Peffers</surname><given-names>MJ</given-names></name>, <name><surname>Fang</surname><given-names>Y</given-names></name>, <name><surname>Cheung</surname><given-names>K</given-names></name>, <name><surname>Wei</surname><given-names>TK</given-names></name>, <name><surname>Clegg</surname><given-names>PD</given-names></name>, <name><surname>Birch</surname><given-names>HL</given-names></name>. <article-title>Transcriptome analysis of ageing in uninjured human Achilles tendon</article-title>. <source>Arthritis research &#x00026; therapy</source>. <year>2015</year>;<volume>17</volume>:<fpage>33</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13075-015-0544-2">10.1186/s13075-015-0544-2</ext-link></comment> ; PubMed Central PMCID: PMC4355574.<?supplied-pmid 25888722?><pub-id pub-id-type="pmid">25888722</pub-id></mixed-citation></ref><ref id="pone.0160517.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Peffers</surname><given-names>MJ</given-names></name>, <name><surname>Collins</surname><given-names>J</given-names></name>, <name><surname>Fang</surname><given-names>Y</given-names></name>, <name><surname>Goljanek-Whysall</surname><given-names>K</given-names></name>, <name><surname>Rushton</surname><given-names>M</given-names></name>, <name><surname>Loughlin</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Age-related changes in mesenchymal stem cells identified using a multi-omics approach</article-title>. <source>Eur Cell Mater</source>. <year>2016</year>;<volume>31</volume>:<fpage>136</fpage>&#x02013;<lpage>59</lpage>. Epub 2016/02/09. vol031a10 [pii]. .<?supplied-pmid 26853623?><pub-id pub-id-type="pmid">26853623</pub-id></mixed-citation></ref><ref id="pone.0160517.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Kanawa</surname><given-names>M</given-names></name>, <name><surname>Igarashi</surname><given-names>A</given-names></name>, <name><surname>Ronald</surname><given-names>VS</given-names></name>, <name><surname>Higashi</surname><given-names>Y</given-names></name>, <name><surname>Kurihara</surname><given-names>H</given-names></name>, <name><surname>Sugiyama</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Age-dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with fibroblast growth factor-2</article-title>. <source>Cytotherapy</source>. <year>2013</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1062</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcyt.2013.03.015">10.1016/j.jcyt.2013.03.015</ext-link></comment> .<?supplied-pmid 23800732?><pub-id pub-id-type="pmid">23800732</pub-id></mixed-citation></ref><ref id="pone.0160517.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>HJ</given-names></name>, <name><surname>Bahk</surname><given-names>YY</given-names></name>, <name><surname>Choi</surname><given-names>YR</given-names></name>, <name><surname>Shim</surname><given-names>JH</given-names></name>, <name><surname>Han</surname><given-names>SH</given-names></name>, <name><surname>Lee</surname><given-names>JW</given-names></name>. <article-title>A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell</article-title>. <source>Journal of orthopaedic research: official publication of the Orthopaedic Research Society</source>. <year>2006</year>;<volume>24</volume>(<issue>11</issue>):<fpage>2059</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jor.20273">10.1002/jor.20273</ext-link></comment> .<?supplied-pmid 16947300?><pub-id pub-id-type="pmid">16947300</pub-id></mixed-citation></ref><ref id="pone.0160517.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Kapacee</surname><given-names>Z</given-names></name>, <name><surname>Yeung</surname><given-names>CY</given-names></name>, <name><surname>Lu</surname><given-names>Y</given-names></name>, <name><surname>Crabtree</surname><given-names>D</given-names></name>, <name><surname>Holmes</surname><given-names>DF</given-names></name>, <name><surname>Kadler</surname><given-names>KE</given-names></name>. <article-title>Synthesis of embryonic tendon-like tissue by human marrow stromal/mesenchymal stem cells requires a three-dimensional environment and transforming growth factor beta3</article-title>. <source>Matrix biology: journal of the International Society for Matrix Biology</source>. <year>2010</year>;<volume>29</volume>(<issue>8</issue>):<fpage>668</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.matbio.2010.08.005">10.1016/j.matbio.2010.08.005</ext-link></comment> ; PubMed Central PMCID: PMC3611595.<?supplied-pmid 20736064?><pub-id pub-id-type="pmid">20736064</pub-id></mixed-citation></ref><ref id="pone.0160517.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Peffers</surname><given-names>MJ</given-names></name>, <name><surname>Thornton</surname><given-names>DJ</given-names></name>, <name><surname>Clegg</surname><given-names>PD</given-names></name>. <article-title>Characterization of neopeptides in equine articular cartilage degradation</article-title>. <source>Journal of orthopaedic research: official publication of the Orthopaedic Research Society</source>. <year>2016</year>;<volume>34</volume>(<issue>1</issue>):<fpage>106</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jor.22963">10.1002/jor.22963</ext-link></comment> ; PubMed Central PMCID: PMCPMC4737130.<?supplied-pmid 26124002?><pub-id pub-id-type="pmid">26124002</pub-id></mixed-citation></ref><ref id="pone.0160517.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Paul</surname><given-names>H</given-names></name>, <name><surname>Reginato</surname><given-names>AJ</given-names></name>, <name><surname>Schumacher</surname><given-names>HR</given-names></name>. <article-title>Alizarin red S staining as a screening test to detect calcium compounds in synovial fluid</article-title>. <source>Arthritis and rheumatism</source>. <year>1983</year>;<volume>26</volume>(<issue>2</issue>):<fpage>191</fpage>&#x02013;<lpage>200</lpage>. .<?supplied-pmid 6186260?><pub-id pub-id-type="pmid">6186260</pub-id></mixed-citation></ref><ref id="pone.0160517.ref030"><label>30</label><mixed-citation publication-type="book"><name><surname>Bancroft</surname><given-names>JD</given-names></name>, <name><surname>Gamble</surname><given-names>M</given-names></name>, editors. <source>heory and practice of histological techniques</source>: <publisher-name>Elsevier Health Sciences</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="pone.0160517.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Chomczynski</surname><given-names>P</given-names></name>, <name><surname>Sacchi</surname><given-names>N</given-names></name>. <article-title>Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction</article-title>. <source>Anal Biochem</source>. <year>1987</year>;<volume>162</volume>(<issue>1</issue>):<fpage>156</fpage>&#x02013;<lpage>9</lpage>. Epub 1987/04/01. 0003-2697(87)90021-2 [pii]. .<?supplied-pmid 2440339?><pub-id pub-id-type="pmid">2440339</pub-id></mixed-citation></ref><ref id="pone.0160517.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Benjamini</surname><given-names>Y</given-names></name>, <name><surname>Hochberg</surname><given-names>Y</given-names></name>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>Methodology</source>. <year>1995</year>;<volume>57</volume>(<issue>1</issue>):<fpage>289</fpage>&#x02013;<lpage>300</lpage>.</mixed-citation></ref><ref id="pone.0160517.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Pidsley</surname><given-names>R</given-names></name>, <name><surname>CC</surname><given-names>YW</given-names></name>, <name><surname>Volta</surname><given-names>M</given-names></name>, <name><surname>Lunnon</surname><given-names>K</given-names></name>, <name><surname>Mill</surname><given-names>J</given-names></name>, <name><surname>Schalkwyk</surname><given-names>LC</given-names></name>. <article-title>A data-driven approach to preprocessing Illumina 450K methylation array data</article-title>. <source>BMC genomics</source>. <year>2013</year>;<volume>14</volume>:<fpage>293</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-14-293">10.1186/1471-2164-14-293</ext-link></comment> ; PubMed Central PMCID: PMC3769145.<?supplied-pmid 23631413?><pub-id pub-id-type="pmid">23631413</pub-id></mixed-citation></ref><ref id="pone.0160517.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Whitaker</surname><given-names>JW</given-names></name>, <name><surname>Shoemaker</surname><given-names>R</given-names></name>, <name><surname>Boyle</surname><given-names>DL</given-names></name>, <name><surname>Hillman</surname><given-names>J</given-names></name>, <name><surname>Anderson</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype</article-title>. <source>Genome medicine</source>. <year>2013</year>;<volume>5</volume>(<issue>4</issue>):<fpage>40</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/gm444">10.1186/gm444</ext-link></comment> ; PubMed Central PMCID: PMC3706831.<?supplied-pmid 23631487?><pub-id pub-id-type="pmid">23631487</pub-id></mixed-citation></ref><ref id="pone.0160517.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Mi</surname><given-names>H</given-names></name>, <name><surname>Muruganujan</surname><given-names>A</given-names></name>, <name><surname>Thomas</surname><given-names>PD</given-names></name>. <article-title>PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees</article-title>. <source>Nucleic Acids Res</source>. <year>2013</year>;<volume>41</volume>(<issue>Database issue</issue>):<fpage>D377</fpage>&#x02013;<lpage>86</lpage>. Epub 2012/11/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gks1118">10.1093/nar/gks1118</ext-link></comment> gks1118 [pii]. ; PubMed Central PMCID: PMC3531194.<?supplied-pmid 23193289?><pub-id pub-id-type="pmid">23193289</pub-id></mixed-citation></ref><ref id="pone.0160517.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>DW</given-names></name>, <name><surname>Sherman</surname><given-names>BT</given-names></name>, <name><surname>Lempicki</surname><given-names>RA</given-names></name>. <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat Protoc</source>. <year>2009</year>;<volume>4</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02013;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2008.211">10.1038/nprot.2008.211</ext-link>.</comment> ISI:000265781800006. <?supplied-pmid 19131956?><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="pone.0160517.ref037"><label>37</label><mixed-citation publication-type="other">URL3. Ingenuity systems. Ingenuity pathway analysis [<ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com/">http://www.ingenuity.com/</ext-link>]</mixed-citation></ref><ref id="pone.0160517.ref038"><label>38</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</ext-link>.</mixed-citation></ref><ref id="pone.0160517.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>I</given-names></name>, <name><surname>Jakob</surname><given-names>M</given-names></name>, <name><surname>Schafer</surname><given-names>D</given-names></name>, <name><surname>Dick</surname><given-names>W</given-names></name>, <name><surname>Spagnoli</surname><given-names>G</given-names></name>, <name><surname>Heberer</surname><given-names>M</given-names></name>. <article-title>Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2001</year>;<volume>9</volume>(<issue>2</issue>):<fpage>112</fpage>&#x02013;<lpage>8</lpage>. Epub 2001/03/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/joca.2000.0366">10.1053/joca.2000.0366</ext-link></comment> S1063-4584(00)90366-2 [pii]. .<?supplied-pmid 11237658?><pub-id pub-id-type="pmid">11237658</pub-id></mixed-citation></ref><ref id="pone.0160517.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Livak</surname><given-names>KJ</given-names></name>, <name><surname>Schmittgen</surname><given-names>TD</given-names></name>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>Methods</source>. <year>2001</year>;<volume>25</volume>(<issue>4</issue>):<fpage>402</fpage>&#x02013;<lpage>8</lpage>. Epub 2002/02/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/meth.2001.1262">10.1006/meth.2001.1262</ext-link></comment> S1046-2023(01)91262-9 [pii]. .<?supplied-pmid 11846609?><pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="pone.0160517.ref041"><label>41</label><mixed-citation publication-type="book"><name><surname>Mueller</surname><given-names>AM</given-names></name>. <source>A Systems Biology Approach To Musculoskeletal Tissue Engineering: Transcriptomic And Proteomic Analysis Of Cartilage And Tendon Cells</source>. <publisher-loc>Liverpool</publisher-loc>: <publisher-name>University of Liverpool</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="pone.0160517.ref042"><label>42</label><mixed-citation publication-type="other"><ext-link ext-link-type="ftp" xlink:href="ftp://ftp.ensembl.org/pub/release-73/gtf/homo_sapiens/Homo_sapiens.GRCh37.73.gtf.gz">ftp://ftp.ensembl.org/pub/release-73/gtf/homo_sapiens/Homo_sapiens.GRCh37.73.gtf.gz</ext-link> 2015.</mixed-citation></ref><ref id="pone.0160517.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>O'Loughlin</surname><given-names>A</given-names></name>, <name><surname>Lynn</surname><given-names>DJ</given-names></name>, <name><surname>McGee</surname><given-names>M</given-names></name>, <name><surname>Doyle</surname><given-names>S</given-names></name>, <name><surname>McCabe</surname><given-names>M</given-names></name>, <name><surname>Earley</surname><given-names>B</given-names></name>. <article-title>Transcriptomic analysis of the stress response to weaning at housing in bovine leukocytes using RNA-seq technology</article-title>. <source>BMC Genomics</source>. <year>2012</year>;<volume>13</volume>:<fpage>250</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-13-250">10.1186/1471-2164-13-250</ext-link></comment> ; PubMed Central PMCID: PMC3583219.<?supplied-pmid 22708644?><pub-id pub-id-type="pmid">22708644</pub-id></mixed-citation></ref><ref id="pone.0160517.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Buitrago</surname><given-names>DH</given-names></name>, <name><surname>Patnaik</surname><given-names>SK</given-names></name>, <name><surname>Kadota</surname><given-names>K</given-names></name>, <name><surname>Kannisto</surname><given-names>E</given-names></name>, <name><surname>Jones</surname><given-names>DR</given-names></name>, <name><surname>Adusumilli</surname><given-names>PS</given-names></name>. <article-title>Small RNA sequencing for profiling microRNAs in long-term preserved formalin-fixed and paraffin-embedded non-small cell lung cancer tumor specimens</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0121521</fpage> Epub 2015/03/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0121521">10.1371/journal.pone.0121521</ext-link></comment> PONE-D-14-37715 [pii]. ; PubMed Central PMCID: PMC4374839.<?supplied-pmid 25812157?><pub-id pub-id-type="pmid">25812157</pub-id></mixed-citation></ref><ref id="pone.0160517.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>KC</given-names></name>, <name><surname>Yamada</surname><given-names>KA</given-names></name>, <name><surname>Patel</surname><given-names>AY</given-names></name>, <name><surname>Topkara</surname><given-names>VK</given-names></name>, <name><surname>George</surname><given-names>I</given-names></name>, <name><surname>Cheema</surname><given-names>FH</given-names></name>, <etal>et al</etal>
<article-title>Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>(<issue>9</issue>):<fpage>1009</fpage>&#x02013;<lpage>21</lpage>. Epub 2014/01/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003863">10.1161/CIRCULATIONAHA.113.003863</ext-link></comment> CIRCULATIONAHA.113.003863 [pii]. ; PubMed Central PMCID: PMC3967509.<?supplied-pmid 24429688?><pub-id pub-id-type="pmid">24429688</pub-id></mixed-citation></ref><ref id="pone.0160517.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Jjingo</surname><given-names>D</given-names></name>, <name><surname>Conley</surname><given-names>AB</given-names></name>, <name><surname>Yi</surname><given-names>SV</given-names></name>, <name><surname>Lunyak</surname><given-names>VV</given-names></name>, <name><surname>Jordan</surname><given-names>IK</given-names></name>. <article-title>On the presence and role of human gene-body DNA methylation</article-title>. <source>Oncotarget</source>. <year>2012</year>;<volume>3</volume>(<issue>4</issue>):<fpage>462</fpage>&#x02013;<lpage>74</lpage>. Epub 2012/05/12. 497 [pii]. ; PubMed Central PMCID: PMC3380580.<?supplied-pmid 22577155?><pub-id pub-id-type="pmid">22577155</pub-id></mixed-citation></ref><ref id="pone.0160517.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Natsu</surname><given-names>K</given-names></name>, <name><surname>Ochi</surname><given-names>M</given-names></name>, <name><surname>Mochizuki</surname><given-names>Y</given-names></name>, <name><surname>Hachisuka</surname><given-names>H</given-names></name>, <name><surname>Yanada</surname><given-names>S</given-names></name>, <name><surname>Yasunaga</surname><given-names>Y</given-names></name>. <article-title>Allogeneic bone marrow-derived mesenchymal stromal cells promote the regeneration of injured skeletal muscle without differentiation into myofibers</article-title>. <source>Tissue engineering</source>. <year>2004</year>;<volume>10</volume>(<issue>7&#x02013;8</issue>):<fpage>1093</fpage>&#x02013;<lpage>112</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/ten.2004.10.1093">10.1089/ten.2004.10.1093</ext-link></comment> .<?supplied-pmid 15363167?><pub-id pub-id-type="pmid">15363167</pub-id></mixed-citation></ref><ref id="pone.0160517.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Peffers</surname><given-names>MJ</given-names></name>, <name><surname>Collins</surname><given-names>J</given-names></name>, <name><surname>Fang</surname><given-names>Y</given-names></name>, <name><surname>Goljanek-Whysall</surname><given-names>K</given-names></name>, <name><surname>Rushton</surname><given-names>M</given-names></name>, <name><surname>Loughlin</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Age-related changes in mesenchymal stem cells identified using a multi-omics approach</article-title>. <source>European Cells and Materials</source>. <year>2016</year>;accepted.</mixed-citation></ref><ref id="pone.0160517.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Bork</surname><given-names>S</given-names></name>, <name><surname>Pfister</surname><given-names>S</given-names></name>, <name><surname>Witt</surname><given-names>H</given-names></name>, <name><surname>Horn</surname><given-names>P</given-names></name>, <name><surname>Korn</surname><given-names>B</given-names></name>, <name><surname>Ho</surname><given-names>AD</given-names></name>, <etal>et al</etal>
<article-title>DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells</article-title>. <source>Aging Cell</source>. <year>2010</year>;<volume>9</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>63</lpage>. Epub 2009/11/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1474-9726.2009.00535.x">10.1111/j.1474-9726.2009.00535.x</ext-link></comment> ACE535 [pii]. ; PubMed Central PMCID: PMC2814091.<?supplied-pmid 19895632?><pub-id pub-id-type="pmid">19895632</pub-id></mixed-citation></ref><ref id="pone.0160517.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Knuth</surname><given-names>CA</given-names></name>, <name><surname>Clark</surname><given-names>ME</given-names></name>, <name><surname>Meeson</surname><given-names>AP</given-names></name>, <name><surname>Khan</surname><given-names>SK</given-names></name>, <name><surname>Dowen</surname><given-names>DJ</given-names></name>, <name><surname>Deehan</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Low oxygen tension is critical for the culture of human mesenchymal stem cells with strong osteogenic potential from haemarthrosis fluid</article-title>. <source>Stem Cell Rev</source>. <year>2013</year>;<volume>9</volume>(<issue>5</issue>):<fpage>599</fpage>&#x02013;<lpage>608</lpage>. Epub 2013/06/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12015-013-9446-3">10.1007/s12015-013-9446-3</ext-link></comment> .<?supplied-pmid 23760649?><pub-id pub-id-type="pmid">23760649</pub-id></mixed-citation></ref><ref id="pone.0160517.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Delgado-Calle</surname><given-names>J</given-names></name>, <name><surname>Riancho</surname><given-names>JA</given-names></name>. <article-title>The role of DNA methylation in common skeletal disorders</article-title>. <source>Biology (Basel)</source>. <year>2012</year>;<volume>1</volume>(<issue>3</issue>):<fpage>698</fpage>&#x02013;<lpage>713</lpage>. Epub 2012/01/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/biology1030698">10.3390/biology1030698</ext-link></comment> biology1030698 [pii]. ; PubMed Central PMCID: PMC4009801.<?supplied-pmid 24832515?><pub-id pub-id-type="pmid">24832515</pub-id></mixed-citation></ref><ref id="pone.0160517.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Fan</surname><given-names>J</given-names></name>, <name><surname>Liang</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2</article-title>. <source>Stem Cells Dev</source>. <year>2014</year>;<volume>23</volume>(<issue>13</issue>):<fpage>1452</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/scd.2013.0600">10.1089/scd.2013.0600</ext-link></comment> ; PubMed Central PMCID: PMC4066225.<?supplied-pmid 24617339?><pub-id pub-id-type="pmid">24617339</pub-id></mixed-citation></ref><ref id="pone.0160517.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>T</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Fan</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Jin</surname><given-names>L</given-names></name>, <name><surname>Gao</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>miR-21 Modulates the Immunoregulatory Function of Bone Marrow Mesenchymal Stem Cells Through the PTEN/Akt/TGF-beta1 Pathway</article-title>. <source>Stem Cells</source>. <year>2015</year>;<volume>33</volume>(<issue>11</issue>):<fpage>3281</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/stem.2081">10.1002/stem.2081</ext-link></comment> .<?supplied-pmid 26086742?><pub-id pub-id-type="pmid">26086742</pub-id></mixed-citation></ref><ref id="pone.0160517.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Singh</surname><given-names>J</given-names></name>, <name><surname>Alif</surname><given-names>R</given-names></name>, <name><surname>Vazquez-Padron</surname><given-names>RI</given-names></name>, <name><surname>Gomes</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>miR-30e targets IGF2-regulated osteogenesis in bone marrow-derived mesenchymal stem cells, aortic smooth muscle cells, and ApoE-/- mice</article-title>. <source>Cardiovascular research</source>. <year>2015</year>;<volume>106</volume>(<issue>1</issue>):<fpage>131</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvv030">10.1093/cvr/cvv030</ext-link></comment> ; PubMed Central PMCID: PMC4375408.<?supplied-pmid 25678587?><pub-id pub-id-type="pmid">25678587</pub-id></mixed-citation></ref><ref id="pone.0160517.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Laine</surname><given-names>SK</given-names></name>, <name><surname>Alm</surname><given-names>JJ</given-names></name>, <name><surname>Virtanen</surname><given-names>SP</given-names></name>, <name><surname>Aro</surname><given-names>HT</given-names></name>, <name><surname>Laitala-Leinonen</surname><given-names>TK</given-names></name>. <article-title>MicroRNAs miR-96, miR-124, and miR-199a regulate gene expression in human bone marrow-derived mesenchymal stem cells</article-title>. <source>J Cell Biochem</source>. <year>2012</year>;<volume>113</volume>(<issue>8</issue>):<fpage>2687</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcb.24144">10.1002/jcb.24144</ext-link></comment> .<?supplied-pmid 22441842?><pub-id pub-id-type="pmid">22441842</pub-id></mixed-citation></ref><ref id="pone.0160517.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>JM</given-names></name>, <name><surname>Tao</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>DD</given-names></name>, <name><surname>Cai</surname><given-names>JJ</given-names></name>, <name><surname>Irani</surname><given-names>K</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>MicroRNA miR-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus</article-title>. <source>Arteriosclerosis, thrombosis, and vascular biology</source>. <year>2014</year>;<volume>34</volume>(<issue>1</issue>):<fpage>99</fpage>&#x02013;<lpage>109</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/ATVBAHA.113.302104">10.1161/ATVBAHA.113.302104</ext-link></comment> .<?supplied-pmid 24177325?><pub-id pub-id-type="pmid">24177325</pub-id></mixed-citation></ref><ref id="pone.0160517.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>Y</given-names></name>, <name><surname>Inloes</surname><given-names>JB</given-names></name>, <name><surname>Katagiri</surname><given-names>T</given-names></name>, <name><surname>Kobayashi</surname><given-names>T</given-names></name>. <article-title>Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling</article-title>. <source>Mol Cell Biol</source>. <year>2011</year>;<volume>31</volume>(<issue>14</issue>):<fpage>3019</fpage>&#x02013;<lpage>28</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.05178-11">10.1128/MCB.05178-11</ext-link></comment> ; PubMed Central PMCID: PMC3133397.<?supplied-pmid 21576357?><pub-id pub-id-type="pmid">21576357</pub-id></mixed-citation></ref><ref id="pone.0160517.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Pivetta</surname><given-names>E</given-names></name>, <name><surname>Scapolan</surname><given-names>M</given-names></name>, <name><surname>Pecolo</surname><given-names>M</given-names></name>, <name><surname>Wassermann</surname><given-names>B</given-names></name>, <name><surname>Abu-Rumeileh</surname><given-names>I</given-names></name>, <name><surname>Balestreri</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases</article-title>. <source>Breast cancer research: BCR</source>. <year>2011</year>;<volume>13</volume>(<issue>5</issue>):<fpage>R105</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/bcr3047">10.1186/bcr3047</ext-link></comment> ; PubMed Central PMCID: PMC3262218.<?supplied-pmid 22032644?><pub-id pub-id-type="pmid">22032644</pub-id></mixed-citation></ref><ref id="pone.0160517.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Le</surname><given-names>LT</given-names></name>, <name><surname>Swingler</surname><given-names>TE</given-names></name>, <name><surname>Crowe</surname><given-names>N</given-names></name>, <name><surname>Vincent</surname><given-names>TL</given-names></name>, <name><surname>Barter</surname><given-names>MJ</given-names></name>, <name><surname>Donell</surname><given-names>ST</given-names></name>, <etal>et al</etal>
<article-title>The microRNA-29 family in cartilage homeostasis and osteoarthritis</article-title>. <source>Journal of molecular medicine</source>. <year>2015</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00109-015-1374-z">10.1007/s00109-015-1374-z</ext-link></comment> .<?supplied-pmid 26687115?><pub-id pub-id-type="pmid">26687115</pub-id></mixed-citation></ref><ref id="pone.0160517.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Kawase</surname><given-names>Y</given-names></name>, <name><surname>Hoshino</surname><given-names>T</given-names></name>, <name><surname>Yokota</surname><given-names>K</given-names></name>, <name><surname>Kuzuhara</surname><given-names>A</given-names></name>, <name><surname>Nakamura</surname><given-names>M</given-names></name>, <name><surname>Maeda</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Bone malformations in interleukin-18 transgenic mice</article-title>. <source>J Bone Miner Res</source>. <year>2003</year>;<volume>18</volume>(<issue>6</issue>):<fpage>975</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1359/jbmr.2003.18.6.975">10.1359/jbmr.2003.18.6.975</ext-link></comment> .<?supplied-pmid 12817749?><pub-id pub-id-type="pmid">12817749</pub-id></mixed-citation></ref><ref id="pone.0160517.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Beyer</surname><given-names>I</given-names></name>, <name><surname>Persson</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Richter</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses</article-title>. <source>Journal of virology</source>. <year>2012</year>;<volume>86</volume>(<issue>11</issue>):<fpage>6286</fpage>&#x02013;<lpage>302</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00205-12">10.1128/JVI.00205-12</ext-link></comment> ; PubMed Central PMCID: PMC3372198.<?supplied-pmid 22457526?><pub-id pub-id-type="pmid">22457526</pub-id></mixed-citation></ref><ref id="pone.0160517.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>Fei</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>J</given-names></name>, <name><surname>Gu</surname><given-names>S</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome</article-title>. <source>Haematologica</source>. <year>2015</year>;<volume>100</volume>(<issue>2</issue>):<fpage>194</fpage>&#x02013;<lpage>204</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3324/haematol.2014.109769">10.3324/haematol.2014.109769</ext-link></comment> ; PubMed Central PMCID: PMC4803146.<?supplied-pmid 25361944?><pub-id pub-id-type="pmid">25361944</pub-id></mixed-citation></ref><ref id="pone.0160517.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Tong</surname><given-names>Z</given-names></name>, <name><surname>Lin</surname><given-names>J</given-names></name>, <name><surname>Yu</surname><given-names>Q</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Decreased osteogenesis of adult mesenchymal stem cells by reactive oxygen species under cyclic stretch: a possible mechanism of age related osteoporosis</article-title>. <source>Bone research</source>. <year>2015</year>;<volume>3</volume>:<fpage>15003</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/boneres.2015.3">10.1038/boneres.2015.3</ext-link></comment> ; PubMed Central PMCID: PMC4413016.<?supplied-pmid 26273536?><pub-id pub-id-type="pmid">26273536</pub-id></mixed-citation></ref><ref id="pone.0160517.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Millar</surname><given-names>NL</given-names></name>, <name><surname>Gilchrist</surname><given-names>DS</given-names></name>, <name><surname>Akbar</surname><given-names>M</given-names></name>, <name><surname>Reilly</surname><given-names>JH</given-names></name>, <name><surname>Kerr</surname><given-names>SC</given-names></name>, <name><surname>Campbell</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease</article-title>. <source>Nature communications</source>. <year>2015</year>;<volume>6</volume>:<fpage>6774</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms7774">10.1038/ncomms7774</ext-link></comment> ; PubMed Central PMCID: PMC4403384.<?supplied-pmid 25857925?><pub-id pub-id-type="pmid">25857925</pub-id></mixed-citation></ref><ref id="pone.0160517.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Mendias</surname><given-names>CL</given-names></name>, <name><surname>Gumucio</surname><given-names>JP</given-names></name>, <name><surname>Lynch</surname><given-names>EB</given-names></name>. <article-title>Mechanical loading and TGF-beta change the expression of multiple miRNAs in tendon fibroblasts</article-title>. <source>Journal of applied physiology</source>. <year>2012</year>;<volume>113</volume>(<issue>1</issue>):<fpage>56</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/japplphysiol.00301.2012">10.1152/japplphysiol.00301.2012</ext-link></comment> ; PubMed Central PMCID: PMC3404830.<?supplied-pmid 22539168?><pub-id pub-id-type="pmid">22539168</pub-id></mixed-citation></ref><ref id="pone.0160517.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>YP</given-names></name>, <name><surname>Peng</surname><given-names>XY</given-names></name>, <name><surname>Li</surname><given-names>ZH</given-names></name>, <name><surname>Chen</surname><given-names>FH</given-names></name>. <article-title>Hyperglycemic effects of a periocular dexamethasone injection in diabetic patients after vitreoretinal surgery</article-title>. <source>Biomedical and environmental sciences: BES</source>. <year>2012</year>;<volume>25</volume>(<issue>3</issue>):<fpage>311</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3967/0895-3988.2012.03.009">10.3967/0895-3988.2012.03.009</ext-link></comment> .<?supplied-pmid 22840582?><pub-id pub-id-type="pmid">22840582</pub-id></mixed-citation></ref><ref id="pone.0160517.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Grammatikakis</surname><given-names>I</given-names></name>, <name><surname>Panda</surname><given-names>AC</given-names></name>, <name><surname>Abdelmohsen</surname><given-names>K</given-names></name>, <name><surname>Gorospe</surname><given-names>M</given-names></name>. <article-title>Long noncoding RNAs (lncRNAs) and the molecular hallmarks of aging</article-title>. <source>Ageing</source>
<year>2014</year>;<volume>6</volume>(<issue>12</issue>):<fpage>992</fpage>&#x02013;<lpage>1009</lpage>.</mixed-citation></ref><ref id="pone.0160517.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Mercer</surname><given-names>TR</given-names></name>, <name><surname>Dinger</surname><given-names>ME</given-names></name>, <name><surname>Mattick</surname><given-names>JS</given-names></name>. <article-title>Long non-coding RNAs: insights into functions</article-title>. <source>Nat Rev Genet</source>. <year>2009</year>;<volume>10</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02013;<lpage>9</lpage>. Epub 2009/02/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrg2521">10.1038/nrg2521</ext-link></comment> nrg2521 [pii]. .<?supplied-pmid 19188922?><pub-id pub-id-type="pmid">19188922</pub-id></mixed-citation></ref><ref id="pone.0160517.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Abdelmohsen</surname><given-names>K</given-names></name>, <name><surname>Panda</surname><given-names>A</given-names></name>, <name><surname>Kang</surname><given-names>MJ</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Selimyan</surname><given-names>R</given-names></name>, <name><surname>Yoon</surname><given-names>JH</given-names></name>, <etal>et al</etal>
<article-title>Senescence-associated lncRNAs: senescence-associated long noncoding RNAs</article-title>. <source>Aging Cell</source>. <year>2013</year>;<volume>12</volume>(<issue>5</issue>):<fpage>890</fpage>&#x02013;<lpage>900</lpage>. Epub 2013/06/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/acel.12115">10.1111/acel.12115</ext-link></comment> ; PubMed Central PMCID: PMC3773026.<?supplied-pmid 23758631?><pub-id pub-id-type="pmid">23758631</pub-id></mixed-citation></ref><ref id="pone.0160517.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Aloe</surname><given-names>L</given-names></name>, <name><surname>Tuveri</surname><given-names>MA</given-names></name>, <name><surname>Carcassi</surname><given-names>U</given-names></name>, <name><surname>Levi-Montalcini</surname><given-names>R</given-names></name>. <article-title>Nerve growth factor in the synovial fluid of patients with chronic arthritis</article-title>. <source>Arthritis and rheumatism</source>. <year>1992</year>;<volume>35</volume>(<issue>3</issue>):<fpage>351</fpage>&#x02013;<lpage>5</lpage>. Epub 1992/03/01. .<?supplied-pmid 1536673?><pub-id pub-id-type="pmid">1536673</pub-id></mixed-citation></ref><ref id="pone.0160517.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Nockher</surname><given-names>WA</given-names></name>, <name><surname>Renz</surname><given-names>H</given-names></name>. <article-title>Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation</article-title>. <source>Clin Chim Acta</source>. <year>2005</year>;<volume>352</volume>(<issue>1&#x02013;2</issue>):<fpage>49</fpage>&#x02013;<lpage>74</lpage>. Epub 2005/01/18. S0009-8981(04)00478-4 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cccn.2004.10.002">10.1016/j.cccn.2004.10.002</ext-link></comment> .<?supplied-pmid 15653100?><pub-id pub-id-type="pmid">15653100</pub-id></mixed-citation></ref><ref id="pone.0160517.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Iannone</surname><given-names>F</given-names></name>, <name><surname>De Bari</surname><given-names>C</given-names></name>, <name><surname>Dell'Accio</surname><given-names>F</given-names></name>, <name><surname>Covelli</surname><given-names>M</given-names></name>, <name><surname>Patella</surname><given-names>V</given-names></name>, <name><surname>Lo Bianco</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes</article-title>. <source>Rheumatology (Oxford)</source>. <year>2002</year>;<volume>41</volume>(<issue>12</issue>):<fpage>1413</fpage>&#x02013;<lpage>8</lpage>. Epub 2002/12/07. .<?supplied-pmid 12468822?><pub-id pub-id-type="pmid">12468822</pub-id></mixed-citation></ref><ref id="pone.0160517.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Grimsholm</surname><given-names>O</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Ny</surname><given-names>T</given-names></name>, <name><surname>Forsgren</surname><given-names>S</given-names></name>. <article-title>Expression patterns of neurotrophins and neurotrophin receptors in articular chondrocytes and inflammatory infiltrates in knee joint arthritis</article-title>. <source>Cells Tissues Organs</source>. <year>2008</year>;<volume>188</volume>(<issue>3</issue>):<fpage>299</fpage>&#x02013;<lpage>309</lpage>. Epub 2008/03/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000121432">10.1159/000121432</ext-link></comment> 000121432 [pii]. .<?supplied-pmid 18349525?><pub-id pub-id-type="pmid">18349525</pub-id></mixed-citation></ref><ref id="pone.0160517.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Katoh-Semba</surname><given-names>R</given-names></name>, <name><surname>Semba</surname><given-names>R</given-names></name>, <name><surname>Takeuchi</surname><given-names>IK</given-names></name>, <name><surname>Kato</surname><given-names>K</given-names></name>. <article-title>Age-related changes in levels of brain-derived neurotrophic factor in selected brain regions of rats, normal mice and senescence-accelerated mice: a comparison to those of nerve growth factor and neurotrophin-3</article-title>. <source>Neurosci Res</source>. <year>1998</year>;<volume>31</volume>(<issue>3</issue>):<fpage>227</fpage>&#x02013;<lpage>34</lpage>. Epub 1998/11/11. S0168-0102(98)00040-6 [pii]. .<?supplied-pmid 9809668?><pub-id pub-id-type="pmid">9809668</pub-id></mixed-citation></ref><ref id="pone.0160517.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Stelnicki</surname><given-names>EJ</given-names></name>, <name><surname>Komuves</surname><given-names>LG</given-names></name>, <name><surname>Kwong</surname><given-names>AO</given-names></name>, <name><surname>Holmes</surname><given-names>D</given-names></name>, <name><surname>Klein</surname><given-names>P</given-names></name>, <name><surname>Rozenfeld</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>HOX homeobox genes exhibit spatial and temporal changes in expression during human skin development</article-title>. <source>The Journal of investigative dermatology</source>. <year>1998</year>;<volume>110</volume>(<issue>2</issue>):<fpage>110</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1046/j.1523-1747.1998.00092.x">10.1046/j.1523-1747.1998.00092.x</ext-link></comment> .<?supplied-pmid 9457903?><pub-id pub-id-type="pmid">9457903</pub-id></mixed-citation></ref><ref id="pone.0160517.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Ackema</surname><given-names>KB</given-names></name>, <name><surname>Charite</surname><given-names>J</given-names></name>. <article-title>Mesenchymal stem cells from different organs are characterized by distinct topographic Hox codes</article-title>. <source>Stem Cells Dev</source>. <year>2008</year>;<volume>17</volume>(<issue>5</issue>):<fpage>979</fpage>&#x02013;<lpage>91</lpage>. Epub 2008/06/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/scd.2007.0220">10.1089/scd.2007.0220</ext-link></comment> .<?supplied-pmid 18533811?><pub-id pub-id-type="pmid">18533811</pub-id></mixed-citation></ref><ref id="pone.0160517.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>JW</given-names></name>, <name><surname>Tsai</surname><given-names>HL</given-names></name>, <name><surname>Chen</surname><given-names>CW</given-names></name>, <name><surname>Yang</surname><given-names>HW</given-names></name>, <name><surname>Yang</surname><given-names>AH</given-names></name>, <name><surname>Yang</surname><given-names>LY</given-names></name>, <etal>et al</etal>
<article-title>Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial-to-mesenchymal transition and immune modulation</article-title>. <source>Journal of cellular and molecular medicine</source>. <year>2012</year>;<volume>16</volume>(<issue>12</issue>):<fpage>2935</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1582-4934.2012.01610.x">10.1111/j.1582-4934.2012.01610.x</ext-link></comment> ; PubMed Central PMCID: PMC4393722.<?supplied-pmid 22862802?><pub-id pub-id-type="pmid">22862802</pub-id></mixed-citation></ref><ref id="pone.0160517.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Poulsen</surname><given-names>RC</given-names></name>, <name><surname>Knowles</surname><given-names>HJ</given-names></name>, <name><surname>Carr</surname><given-names>AJ</given-names></name>, <name><surname>Hulley</surname><given-names>PA</given-names></name>. <article-title>Cell differentiation versus cell death: extracellular glucose is a key determinant of cell fate following oxidative stress exposure</article-title>. <source>Cell Death Dis</source>. <year>2014</year>;<volume>5</volume>:<fpage>e1074</fpage> Epub 2014/02/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/cddis.2014.52">10.1038/cddis.2014.52</ext-link></comment> cddis201452 [pii]. ; PubMed Central PMCID: PMC3944267.<?supplied-pmid 24556689?><pub-id pub-id-type="pmid">24556689</pub-id></mixed-citation></ref><ref id="pone.0160517.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Collins</surname><given-names>JA</given-names></name>, <name><surname>Wood</surname><given-names>ST</given-names></name>, <name><surname>Nelson</surname><given-names>KJ</given-names></name>, <name><surname>Rowe</surname><given-names>MA</given-names></name>, <name><surname>Carlson</surname><given-names>CS</given-names></name>, <name><surname>Chubinskaya</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Oxidative Stress Promotes Peroxiredoxin Hyperoxidation and Attenuates Pro-survival Signalling in Aging Chondrocytes</article-title>. <source>J Biol Chem</source>. <year>2016</year> Epub 2016/01/23. jbc.M115.693523 [pii]M115.693523 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M115.693523">10.1074/jbc.M115.693523</ext-link></comment> .<?supplied-pmid 26797130?><pub-id pub-id-type="pmid">26797130</pub-id></mixed-citation></ref><ref id="pone.0160517.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>DC</given-names></name>. <article-title>Mitochondria: dynamic organelles in disease, aging, and development</article-title>. <source>Cell</source>. <year>2006</year>;<volume>125</volume>(<issue>7</issue>):<fpage>1241</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2006.06.010">10.1016/j.cell.2006.06.010</ext-link></comment> .<?supplied-pmid 16814712?><pub-id pub-id-type="pmid">16814712</pub-id></mixed-citation></ref><ref id="pone.0160517.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Loeser</surname><given-names>RF</given-names></name>, <name><surname>Gandhi</surname><given-names>U</given-names></name>, <name><surname>Long</surname><given-names>DL</given-names></name>, <name><surname>Yin</surname><given-names>W</given-names></name>, <name><surname>Chubinskaya</surname><given-names>S</given-names></name>. <article-title>Aging and oxidative stress reduce the response of human articular chondrocytes to insulin-like growth factor 1 and osteogenic protein 1</article-title>. <source>Arthritis Rheumatol</source>. <year>2014</year>;<volume>66</volume>(<issue>8</issue>):<fpage>2201</fpage>&#x02013;<lpage>9</lpage>. Epub 2014/03/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.38641">10.1002/art.38641</ext-link></comment> ; PubMed Central PMCID: PMC4116467.<?supplied-pmid 24664641?><pub-id pub-id-type="pmid">24664641</pub-id></mixed-citation></ref><ref id="pone.0160517.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Henrotin</surname><given-names>YE</given-names></name>, <name><surname>Bruckner</surname><given-names>P</given-names></name>, <name><surname>Pujol</surname><given-names>JP</given-names></name>. <article-title>The role of reactive oxygen species in homeostasis and degradation of cartilage</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2003</year>;<volume>11</volume>(<issue>10</issue>):<fpage>747</fpage>&#x02013;<lpage>55</lpage>. Epub 2003/09/18. S106345840300150X [pii]. .<?supplied-pmid 13129694?><pub-id pub-id-type="pmid">13129694</pub-id></mixed-citation></ref><ref id="pone.0160517.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Guan</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Breyer</surname><given-names>MD</given-names></name>. <article-title>The Role of PPARs in the Transcriptional Control of Cellular Processes</article-title>. <source>Drug News Perspect</source>. <year>2002</year>;<volume>15</volume>(<issue>3</issue>):<fpage>147</fpage>&#x02013;<lpage>54</lpage>. Epub 2003/04/05. 294 [pii]. .<?supplied-pmid 12677257?><pub-id pub-id-type="pmid">12677257</pub-id></mixed-citation></ref><ref id="pone.0160517.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Lotz</surname><given-names>M</given-names></name>, <name><surname>Terkeltaub</surname><given-names>R</given-names></name>, <name><surname>Liu-Bryan</surname><given-names>R</given-names></name>. <article-title>Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor gamma coactivator 1alpha</article-title>. <source>Arthritis Rheumatol</source>. <year>2015</year>;<volume>67</volume>(<issue>8</issue>):<fpage>2141</fpage>&#x02013;<lpage>53</lpage>. Epub 2015/05/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.39182">10.1002/art.39182</ext-link></comment> ; PubMed Central PMCID: PMC4519411.<?supplied-pmid 25940958?><pub-id pub-id-type="pmid">25940958</pub-id></mixed-citation></ref><ref id="pone.0160517.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Haussler</surname><given-names>MR</given-names></name>, <name><surname>Whitfield</surname><given-names>GK</given-names></name>, <name><surname>Haussler</surname><given-names>CA</given-names></name>, <name><surname>Hsieh</surname><given-names>JC</given-names></name>, <name><surname>Thompson</surname><given-names>PD</given-names></name>, <name><surname>Selznick</surname><given-names>SH</given-names></name>, <etal>et al</etal>
<article-title>The nuclear vitamin D receptor: biological and molecular regulatory properties revealed</article-title>. <source>J Bone Miner Res</source>. <year>1998</year>;<volume>13</volume>(<issue>3</issue>):<fpage>325</fpage>&#x02013;<lpage>49</lpage>. Epub 1998/04/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1359/jbmr.1998.13.3.325">10.1359/jbmr.1998.13.3.325</ext-link></comment> .<?supplied-pmid 9525333?><pub-id pub-id-type="pmid">9525333</pub-id></mixed-citation></ref><ref id="pone.0160517.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Goltzman</surname><given-names>D</given-names></name>. <article-title>Discoveries, drugs and skeletal disorders</article-title>. <source>Nat Rev Drug Discov</source>. <year>2002</year>;<volume>1</volume>(<issue>10</issue>):<fpage>784</fpage>&#x02013;<lpage>96</lpage>. Epub 2002/10/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd916">10.1038/nrd916</ext-link></comment> nrd916 [pii]. .<?supplied-pmid 12360256?><pub-id pub-id-type="pmid">12360256</pub-id></mixed-citation></ref><ref id="pone.0160517.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Horst</surname><given-names>RL</given-names></name>, <name><surname>Goff</surname><given-names>JP</given-names></name>, <name><surname>Reinhardt</surname><given-names>TA</given-names></name>. <article-title>Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor</article-title>. <source>Endocrinology</source>. <year>1990</year>;<volume>126</volume>(<issue>2</issue>):<fpage>1053</fpage>&#x02013;<lpage>7</lpage>. Epub 1990/02/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1210/endo-126-2-1053">10.1210/endo-126-2-1053</ext-link></comment> .<?supplied-pmid 2153518?><pub-id pub-id-type="pmid">2153518</pub-id></mixed-citation></ref><ref id="pone.0160517.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Duque</surname><given-names>G</given-names></name>, <name><surname>El Abdaimi</surname><given-names>K</given-names></name>, <name><surname>Macoritto</surname><given-names>M</given-names></name>, <name><surname>Miller</surname><given-names>MM</given-names></name>, <name><surname>Kremer</surname><given-names>R</given-names></name>. <article-title>Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2002</year>;<volume>299</volume>(<issue>3</issue>):<fpage>446</fpage>&#x02013;<lpage>54</lpage>. Epub 2002/11/26. S0006291X02026578 [pii]. .<?supplied-pmid 12445821?><pub-id pub-id-type="pmid">12445821</pub-id></mixed-citation></ref><ref id="pone.0160517.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Gerstenfeld</surname><given-names>LC</given-names></name>, <name><surname>Zurakowski</surname><given-names>D</given-names></name>, <name><surname>Schaffer</surname><given-names>JL</given-names></name>, <name><surname>Nichols</surname><given-names>DP</given-names></name>, <name><surname>Toma</surname><given-names>CD</given-names></name>, <name><surname>Broess</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Variable hormone responsiveness of osteoblast populations isolated at different stages of embryogenesis and its relationship to the osteogenic lineage</article-title>. <source>Endocrinology</source>. <year>1996</year>;<volume>137</volume>(<issue>9</issue>):<fpage>3957</fpage>&#x02013;<lpage>68</lpage>. Epub 1996/09/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1210/endo.137.9.8756572">10.1210/endo.137.9.8756572</ext-link></comment> .<?supplied-pmid 8756572?><pub-id pub-id-type="pmid">8756572</pub-id></mixed-citation></ref><ref id="pone.0160517.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Kretlow</surname><given-names>JD</given-names></name>, <name><surname>Jin</surname><given-names>YQ</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>WJ</given-names></name>, <name><surname>Hong</surname><given-names>TH</given-names></name>, <name><surname>Zhou</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells</article-title>. <source>BMC Cell Biol</source>. <year>2008</year>;<volume>9</volume>:<fpage>60</fpage> Epub 2008/10/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2121-9-60">10.1186/1471-2121-9-60</ext-link></comment> 1471-2121-9-60 [pii]. ; PubMed Central PMCID: PMC2584028.<?supplied-pmid 18957087?><pub-id pub-id-type="pmid">18957087</pub-id></mixed-citation></ref><ref id="pone.0160517.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Liu-Bryan</surname><given-names>R</given-names></name>, <name><surname>Terkeltaub</surname><given-names>R</given-names></name>. <article-title>Emerging regulators of the inflammatory process in osteoarthritis</article-title>. <source>Nat Rev Rheumatol</source>. <year>2015</year>;<volume>11</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>44</lpage>. Epub 2014/10/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrrheum.2014.162">10.1038/nrrheum.2014.162</ext-link></comment> nrrheum.2014.162 [pii]. ; PubMed Central PMCID: PMC4374654.<?supplied-pmid 25266449?><pub-id pub-id-type="pmid">25266449</pub-id></mixed-citation></ref><ref id="pone.0160517.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Kharaz</surname><given-names>YA</given-names></name>, <name><surname>Tew</surname><given-names>SR</given-names></name>, <name><surname>Peffers</surname><given-names>M</given-names></name>, <name><surname>Canty-Laird</surname><given-names>EG</given-names></name>, <name><surname>Comerford</surname><given-names>E</given-names></name>. <article-title>Proteomic differences between native and tissue-engineered tendon and ligament</article-title>. <source>Proteomics</source>. <year>2016</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1547</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pmic.201500459">10.1002/pmic.201500459</ext-link></comment> .<?supplied-pmid 27080496?><pub-id pub-id-type="pmid">27080496</pub-id></mixed-citation></ref><ref id="pone.0160517.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Paxton</surname><given-names>JZ</given-names></name>, <name><surname>Hagerty</surname><given-names>P</given-names></name>, <name><surname>Andrick</surname><given-names>JJ</given-names></name>, <name><surname>Baar</surname><given-names>K</given-names></name>. <article-title>Optimizing an intermittent stretch paradigm using ERK1/2 phosphorylation results in increased collagen synthesis in engineered ligaments</article-title>. <source>Tissue Eng Part A</source>. <year>2012</year>;<volume>18</volume>(<issue>3&#x02013;4</issue>):<fpage>277</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/ten.TEA.2011.0336">10.1089/ten.TEA.2011.0336</ext-link></comment> ; PubMed Central PMCID: PMCPMC3267962.<?supplied-pmid 21902469?><pub-id pub-id-type="pmid">21902469</pub-id></mixed-citation></ref><ref id="pone.0160517.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>ET</given-names></name>, <name><surname>Sandberg</surname><given-names>R</given-names></name>, <name><surname>Luo</surname><given-names>S</given-names></name>, <name><surname>Khrebtukova</surname><given-names>I</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Mayr</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Alternative isoform regulation in human tissue transcriptomes</article-title>. <source>Nature</source>. <year>2008</year>;<volume>456</volume>(<issue>7221</issue>):<fpage>470</fpage>&#x02013;<lpage>6</lpage>. Epub 2008/11/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature07509">10.1038/nature07509</ext-link></comment> nature07509 [pii]. ; PubMed Central PMCID: PMC2593745.<?supplied-pmid 18978772?><pub-id pub-id-type="pmid">18978772</pub-id></mixed-citation></ref><ref id="pone.0160517.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Shargunov</surname><given-names>AV</given-names></name>, <name><surname>Krasnov</surname><given-names>GS</given-names></name>, <name><surname>Ponomarenko</surname><given-names>EA</given-names></name>, <name><surname>Lisitsa</surname><given-names>AV</given-names></name>, <name><surname>Shurdov</surname><given-names>MA</given-names></name>, <name><surname>Zverev</surname><given-names>VV</given-names></name>, <etal>et al</etal>
<article-title>Tissue-specific alternative splicing analysis reveals the diversity of chromosome 18 transcriptome</article-title>. <source>J Proteome Res</source>. <year>2014</year>;<volume>13</volume>(<issue>1</issue>):<fpage>173</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/pr400808u">10.1021/pr400808u</ext-link></comment> .<?supplied-pmid 24320163?><pub-id pub-id-type="pmid">24320163</pub-id></mixed-citation></ref><ref id="pone.0160517.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>McAlinden</surname><given-names>A</given-names></name>. <article-title>Alternative splicing of type II procollagen: IIB or not IIB?</article-title>
<source>Connect Tissue Res</source>. <year>2014</year>;<volume>55</volume>(<issue>3</issue>):<fpage>165</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/03008207.2014.908860">10.3109/03008207.2014.908860</ext-link></comment> ; PubMed Central PMCID: PMCPMC4317353.<?supplied-pmid 24669942?><pub-id pub-id-type="pmid">24669942</pub-id></mixed-citation></ref><ref id="pone.0160517.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Tazi</surname><given-names>J</given-names></name>, <name><surname>Bakkour</surname><given-names>N</given-names></name>, <name><surname>Stamm</surname><given-names>S</given-names></name>. <article-title>Alternative splicing and disease</article-title>. <source>Biochim Biophys Acta</source>. <year>2009</year>;<volume>1792</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbadis.2008.09.017">10.1016/j.bbadis.2008.09.017</ext-link></comment> .<?supplied-pmid 18992329?><pub-id pub-id-type="pmid">18992329</pub-id></mixed-citation></ref><ref id="pone.0160517.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Prinos</surname><given-names>P</given-names></name>, <name><surname>Garneau</surname><given-names>D</given-names></name>, <name><surname>Lucier</surname><given-names>JF</given-names></name>, <name><surname>Gendron</surname><given-names>D</given-names></name>, <name><surname>Couture</surname><given-names>S</given-names></name>, <name><surname>Boivin</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Alternative splicing of SYK regulates mitosis and cell survival</article-title>. <source>Nat Struct Mol Biol</source>. <year>2011</year>;<volume>18</volume>(<issue>6</issue>):<fpage>673</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nsmb.2040">10.1038/nsmb.2040</ext-link></comment> .<?supplied-pmid 21552259?><pub-id pub-id-type="pmid">21552259</pub-id></mixed-citation></ref><ref id="pone.0160517.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Sheng</surname><given-names>JJ</given-names></name>, <name><surname>Jin</surname><given-names>JP</given-names></name>. <article-title>Gene regulation, alternative splicing, and posttranslational modification of troponin subunits in cardiac development and adaptation: a focused review</article-title>. <source>Front Physiol</source>. <year>2014</year>;<volume>5</volume>:<fpage>165</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fphys.2014.00165">10.3389/fphys.2014.00165</ext-link></comment> ; PubMed Central PMCID: PMCPMC4012202.<?supplied-pmid 24817852?><pub-id pub-id-type="pmid">24817852</pub-id></mixed-citation></ref><ref id="pone.0160517.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Harries</surname><given-names>LW</given-names></name>, <name><surname>Hernandez</surname><given-names>D</given-names></name>, <name><surname>Henley</surname><given-names>W</given-names></name>, <name><surname>Wood</surname><given-names>AR</given-names></name>, <name><surname>Holly</surname><given-names>AC</given-names></name>, <name><surname>Bradley-Smith</surname><given-names>RM</given-names></name>, <etal>et al</etal>
<article-title>Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing</article-title>. <source>Aging Cell</source>. <year>2011</year>;<volume>10</volume>(<issue>5</issue>):<fpage>868</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1474-9726.2011.00726.x">10.1111/j.1474-9726.2011.00726.x</ext-link></comment> ; PubMed Central PMCID: PMCPMC3173580.<?supplied-pmid 21668623?><pub-id pub-id-type="pmid">21668623</pub-id></mixed-citation></ref><ref id="pone.0160517.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>David</surname><given-names>CJ</given-names></name>, <name><surname>Manley</surname><given-names>JL</given-names></name>. <article-title>Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged</article-title>. <source>Genes Dev</source>. <year>2010</year>;<volume>24</volume>(<issue>21</issue>):<fpage>2343</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.1973010">10.1101/gad.1973010</ext-link></comment> ; PubMed Central PMCID: PMCPMC2964746.<?supplied-pmid 21041405?><pub-id pub-id-type="pmid">21041405</pub-id></mixed-citation></ref><ref id="pone.0160517.ref102"><label>102</label><mixed-citation publication-type="journal"><name><surname>Tollervey</surname><given-names>JR</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Hortobagyi</surname><given-names>T</given-names></name>, <name><surname>Witten</surname><given-names>JT</given-names></name>, <name><surname>Zarnack</surname><given-names>K</given-names></name>, <name><surname>Kayikci</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Analysis of alternative splicing associated with aging and neurodegeneration in the human brain</article-title>. <source>Genome Res</source>. <year>2011</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1572</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gr.122226.111">10.1101/gr.122226.111</ext-link></comment> ; PubMed Central PMCID: PMCPMC3202275.<?supplied-pmid 21846794?><pub-id pub-id-type="pmid">21846794</pub-id></mixed-citation></ref><ref id="pone.0160517.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Gang</surname><given-names>H</given-names></name>, <name><surname>Dhingra</surname><given-names>R</given-names></name>, <name><surname>Lin</surname><given-names>J</given-names></name>, <name><surname>Hai</surname><given-names>Y</given-names></name>, <name><surname>Aviv</surname><given-names>Y</given-names></name>, <name><surname>Margulets</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>PDK2-mediated alternative splicing switches Bnip3 from cell death to cell survival</article-title>. <source>J Cell Biol</source>. <year>2015</year>;<volume>210</volume>(<issue>7</issue>):<fpage>1101</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.201504047">10.1083/jcb.201504047</ext-link></comment> ; PubMed Central PMCID: PMCPMC4586742.<?supplied-pmid 26416963?><pub-id pub-id-type="pmid">26416963</pub-id></mixed-citation></ref><ref id="pone.0160517.ref104"><label>104</label><mixed-citation publication-type="journal"><name><surname>Calvanese</surname><given-names>V</given-names></name>, <name><surname>Lara</surname><given-names>E</given-names></name>, <name><surname>Kahn</surname><given-names>A</given-names></name>, <name><surname>Fraga</surname><given-names>MF</given-names></name>. <article-title>The role of epigenetics in aging and age-related diseases</article-title>. <source>Ageing research reviews</source>. <year>2009</year>;<volume>8</volume>(<issue>4</issue>):<fpage>268</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.arr.2009.03.004">10.1016/j.arr.2009.03.004</ext-link></comment> .<?supplied-pmid 19716530?><pub-id pub-id-type="pmid">19716530</pub-id></mixed-citation></ref><ref id="pone.0160517.ref105"><label>105</label><mixed-citation publication-type="journal"><name><surname>Robertson</surname><given-names>KD</given-names></name>, <name><surname>Jones</surname><given-names>PA</given-names></name>. <article-title>DNA methylation: past, present and future directions</article-title>. <source>Carcinogenesis</source>. <year>2000</year>;<volume>21</volume>(<issue>3</issue>):<fpage>461</fpage>&#x02013;<lpage>7</lpage>. .<?supplied-pmid 10688866?><pub-id pub-id-type="pmid">10688866</pub-id></mixed-citation></ref><ref id="pone.0160517.ref106"><label>106</label><mixed-citation publication-type="journal"><name><surname>Robertson</surname><given-names>KD</given-names></name>. <article-title>DNA methylation and human disease</article-title>. <source>Nat Rev Genet</source>. <year>2005</year>;<volume>6</volume>(<issue>8</issue>):<fpage>597</fpage>&#x02013;<lpage>610</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrg1655">10.1038/nrg1655</ext-link></comment> .<?supplied-pmid 16136652?><pub-id pub-id-type="pmid">16136652</pub-id></mixed-citation></ref><ref id="pone.0160517.ref107"><label>107</label><mixed-citation publication-type="journal"><name><surname>Hanzelmann</surname><given-names>S</given-names></name>, <name><surname>Beier</surname><given-names>F</given-names></name>, <name><surname>Gusmao</surname><given-names>EG</given-names></name>, <name><surname>Koch</surname><given-names>CM</given-names></name>, <name><surname>Hummel</surname><given-names>S</given-names></name>, <name><surname>Charapitsa</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Replicative senescence is associated with nuclear reorganization and with DNA methylation at specific transcription factor binding sites</article-title>. <source>Clin Epigenetics</source>. <year>2015</year>;<volume>7</volume>(<issue>1</issue>):<fpage>19</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13148-015-0057-5">10.1186/s13148-015-0057-5</ext-link></comment> ; PubMed Central PMCID: PMCPMC4356053.<?supplied-pmid 25763115?><pub-id pub-id-type="pmid">25763115</pub-id></mixed-citation></ref><ref id="pone.0160517.ref108"><label>108</label><mixed-citation publication-type="journal"><name><surname>Venkataraman</surname><given-names>K</given-names></name>, <name><surname>Futerman</surname><given-names>AH</given-names></name>. <article-title>Do longevity assurance genes containing Hox domains regulate cell development via ceramide synthesis?</article-title>
<source>FEBS Lett</source>. <year>2002</year>;<volume>528</volume>(<issue>1&#x02013;3</issue>):<fpage>3</fpage>&#x02013;<lpage>4</lpage>. Epub 2002/09/26. S0014579302032489 [pii]. .<?supplied-pmid 12297269?><pub-id pub-id-type="pmid">12297269</pub-id></mixed-citation></ref><ref id="pone.0160517.ref109"><label>109</label><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>P</given-names></name>, <name><surname>Boeuf</surname><given-names>S</given-names></name>, <name><surname>Dickhut</surname><given-names>A</given-names></name>, <name><surname>Boehmer</surname><given-names>S</given-names></name>, <name><surname>Olek</surname><given-names>S</given-names></name>, <name><surname>Richter</surname><given-names>W</given-names></name>. <article-title>Correlation of COL10A1 induction during chondrogenesis of mesenchymal stem cells with demethylation of two CpG sites in the COL10A1 promoter</article-title>. <source>Arthritis and rheumatism</source>. <year>2008</year>;<volume>58</volume>(<issue>9</issue>):<fpage>2743</fpage>&#x02013;<lpage>53</lpage>. Epub 2008/09/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.23736">10.1002/art.23736</ext-link></comment> .<?supplied-pmid 18759285?><pub-id pub-id-type="pmid">18759285</pub-id></mixed-citation></ref><ref id="pone.0160517.ref110"><label>110</label><mixed-citation publication-type="journal"><name><surname>Sethe</surname><given-names>S</given-names></name>, <name><surname>Scutt</surname><given-names>A</given-names></name>, <name><surname>Stolzing</surname><given-names>A</given-names></name>. <article-title>Aging of mesenchymal stem cells</article-title>. <source>Ageing research reviews</source>. <year>2006</year>;<volume>5</volume>(<issue>1</issue>):<fpage>91</fpage>&#x02013;<lpage>116</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.arr.2005.10.001">10.1016/j.arr.2005.10.001</ext-link></comment> .<?supplied-pmid 16310414?><pub-id pub-id-type="pmid">16310414</pub-id></mixed-citation></ref><ref id="pone.0160517.ref111"><label>111</label><mixed-citation publication-type="journal"><name><surname>Roura</surname><given-names>S</given-names></name>, <name><surname>Farre</surname><given-names>J</given-names></name>, <name><surname>Soler-Botija</surname><given-names>C</given-names></name>, <name><surname>Llach</surname><given-names>A</given-names></name>, <name><surname>Hove-Madsen</surname><given-names>L</given-names></name>, <name><surname>Cairo</surname><given-names>JJ</given-names></name>, <etal>et al</etal>
<article-title>Effect of aging on the pluripotential capacity of human CD105+ mesenchymal stem cells</article-title>. <source>Eur J Heart Fail</source>. <year>2006</year>;<volume>8</volume>(<issue>6</issue>):<fpage>555</fpage>&#x02013;<lpage>63</lpage>. Epub 2006/03/02. S1388-9842(05)00330-2 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejheart.2005.11.006">10.1016/j.ejheart.2005.11.006</ext-link></comment> .<?supplied-pmid 16507351?><pub-id pub-id-type="pmid">16507351</pub-id></mixed-citation></ref><ref id="pone.0160517.ref112"><label>112</label><mixed-citation publication-type="journal"><name><surname>McCauley</surname><given-names>BS</given-names></name>, <name><surname>Dang</surname><given-names>W</given-names></name>. <article-title>Histone methylation and aging: lessons learned from model systems</article-title>. <source>Biochim Biophys Acta</source>. <year>2014</year>;<volume>1839</volume>(<issue>12</issue>):<fpage>1454</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbagrm.2014.05.008">10.1016/j.bbagrm.2014.05.008</ext-link></comment> ; PubMed Central PMCID: PMC4240748.<?supplied-pmid 24859460?><pub-id pub-id-type="pmid">24859460</pub-id></mixed-citation></ref></ref-list></back></article>